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Anders Krogh5 and Elena Papaleo1,2*
Abstract
Background: Studies on tumor-secreted microRNAs point to a functional role of these in cellular communication
and reprogramming of the tumor microenvironment. Uptake of tumor-secreted microRNAs by neighboring cells
may result in the silencing of mRNA targets and, in turn, modulation of the transcriptome. Studying miRNAs
externalized from tumors could improve cancer patient diagnosis and disease monitoring and help to pinpoint
which miRNA-gene interactions are central for tumor properties such as invasiveness and metastasis.
Methods: Using a bioinformatics approach, we analyzed the profiles of secreted tumor and normal interstitial fluid
(IF) microRNAs, from women with breast cancer (BC). We carried out differential abundance analysis (DAA), to
obtain miRNAs, which were enriched or depleted in IFs, from patients with different clinical traits. Subsequently,
miRNA family enrichment analysis was performed to assess whether any families were over-represented in the
specific sets. We identified dysregulated genes in tumor tissues from the same cohort of patients and constructed
weighted gene co-expression networks, to extract sets of co-expressed genes and co-abundant miRNAs. Lastly, we
integrated miRNAs and mRNAs to obtain interaction networks and supported our findings using prediction tools
and cancer gene databases.
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Results: Network analysis showed co-expressed genes and miRNA regulators, associated with tumor lymphocyte
infiltration. All of the genes were involved in immune system processes, and many had previously been associated
with cancer immunity. A subset of these, BTLA, CXCL13, IL7R, LAMP3, and LTB, was linked to the presence of tertiary
lymphoid structures and high endothelial venules within tumors. Co-abundant tumor interstitial fluid miRNAs within
this network, including miR-146a and miR-494, were annotated as negative regulators of immune-stimulatory
responses. One co-expression network encompassed differences between BC subtypes. Genes differentially co-
expressed between luminal B and triple-negative breast cancer (TNBC) were connected with sphingolipid
metabolism and predicted to be co-regulated by miR-23a. Co-expressed genes and TIF miRNAs associated with
tumor grade were BTRC, CHST1, miR-10a/b, miR-107, miR-301a, and miR-454.
Conclusion: Integration of IF miRNAs and mRNAs unveiled networks associated with patient clinicopathological
traits, and underlined molecular mechanisms, specific to BC sub-groups. Our results highlight the benefits of an
integrative approach to biomarker discovery, placing secreted miRNAs within a biological context.
Keywords: Tumor interstitial fluid, Breast cancer, Co-expression analysis, Biomarker, Tumor-infiltrating lymphocytes,
Tumor grade, TNBC, miRNA families, Gene target, Interaction networks
Background
Two of the most predictive measures of breast cancer
(BC) patient mortality are tumor progression and immune
infiltration [1–3]. By decoding and recognizing the under-
lying molecular patterns of invasive breast tumors, clini-
cians may provide high-grade tumor patients with
appropriate prognosis and treatment, while monitoring
the potential progression of lower-grade cancers [4, 5].
Breast tumor invasiveness and patient prognosis are re-
lated to molecular subtypes, which are currently classified
through PAM50 mRNA expression or immunohisto-
chemistry staining of hormone receptors [6, 7]. BC pa-
tients with luminal tumors, defined by the expression of
the estrogen and/or progesterone receptor (ER+|−,
PgR+|−), are known to have the best overall outcome [8,
9]. Luminal A type tumors are associated with a slightly
better patient survival rate than luminal B tumors, which
have high expression levels of Ki-67 (> 14%), and in some
cases, human epidermal growth factor receptor 2 (HER2)
amplification [8, 9]. Patients with estrogen- and progester-
one receptor-negative (ER−, PgR−), Her2-amplified tu-
mors, have poorer outcomes than those with luminal
subtypes, even though this group of patients has been
shown to respond well to targeted therapy [10]. The basal-
like and triple-negative breast cancer (TNBC) subtypes,
which are largely overlapping and classified by the lack of
hormone receptor expression (ER−, PgR−, Her2−) [11],
have the poorest prognosis among the subtypes [8, 9].
A precise characterization of the degree of breast
tumor invasiveness, alongside the biological relevant
pathways and underlying molecular mechanisms, hinges
on the identification of a set of specific and sensitive
biomarkers.
Recent studies suggest that circulating microRNAs
may have great potentials as cancer progression markers
[12–14], partially due to their high stability in the
plasma/blood [15, 16]. Not only does the level of exter-
nalized miRNAs reflects the molecular events underlying
tumor progression but, importantly, some studies point
to a functional role of tumor-secreted circulating
miRNA in intracellular communication and tumor re-
programming [17–19]. Tumor cells may release micro-
vesicles into the extracellular space, which may then be
taken up by other cells (tumor, epithelial, or immune)
via endocytosis [20]. Some micro-vesicles have been
found to not only contain mature miRNAs, but pre-
miRNAs with accompanying RNA-induced silencing
complexes (RISCs) [21]. Uptake of the pre-miRNA exo-
somes by recipient cells resulted in an efficient silencing
of target mRNAs and reprogramming of the cellular
transcriptome [22]. In accordance, it has been reported
[23] that the release of miRNAs within exosomes was
not merely a reflection of the abundance of a given
miRNA species, but a selective process facilitated by the
tumor cells [23, 24]. For example, exosome-mediated
transport of miR-10b from BC cell lines has been shown
to promote tumor cell invasiveness in other BC cell
lines, which were otherwise not invasive [24].
Circulating miRNAs may also be found free of exo-
somes, either in complexes with argonaute proteins [25]
or bound by high-density lipoprotein (HDL) [26]. HDL-
bound circulating miRNAs are delivered to recipient
cells, via the scavenger receptor class B/type I-dependent
and uptake of these results in targeting of mRNA re-
porters [26]. MicroRNA silencing of gene targets is facil-
itated through the interaction of the mRNA 3′ UTR,
with the ~ 8 nucleotide seed sequence within the
miRNA [27]. Mature miRNAs, which have identical seed
sequences, are classified as belonging to the same
miRNA family [28]. Because seed sequences of family
members are complementary to the same binding mo-
tifs, these miRNAs are thought to regulate the same
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target genes [27, 28]. In a study from 2013, Hamilton
et al. [29] identified a pan-cancer oncogenic microRNA
family, which was responsible for the co-regulation of
central tumor suppressors and, in general, genes func-
tioning within the same pathways. As members of a
miRNA family can act as gene co-regulators, it is pos-
sible that these are also co-secreted by tumor cells.
Studying the relationship between tumor externalized
miRNAs should identify which biological processes and
pathways are specifically modulated within the tumor
cell itself and potentially targeted in recipient cells.
Indeed, one very interesting aspect of tumor-secreted
miRNA reprogramming is a possible connection to dis-
ease progression through the modification of both
neighboring and distal tissues. Le et al. [30] showed that
exosomes containing miR-200 from metastatic human
breast cancer cell lines were absorbed by non-metastatic
cells, resulting in the promotion of mesenchymal-to-
epithelial transition [30]. The study found that miR-200-
expressing tumors used extracellular vesicles to drive
metastasis of otherwise weakly metastatic cells at distant
sites, providing these cells with the ability to colonize
distant tissues in a miR-200-dependent manner [30].
Similarly, it has been reported that cancer cells can sup-
press glucose uptake by non-tumor cells in the pre-
metastatic niche, by secreting micro-vesicles containing
miR-122 [31]. Repression of miR-122 restored the glu-
cose uptake in distant organs, while decreasing the inci-
dence of metastasis and disease progression [31].
As such, identification of specifically secreted miRNAs
may not only help to improve patient diagnosis/prognosis
and disease monitoring, but could also relay information
about which target genes are central for particular tumor
properties, including invasiveness, and how these proper-
ties may be promoted by tumor cell communication.
Despite their potential usefulness, however, identifica-
tion of robust circulating miRNA biomarkers is no trivial
task, as a range of non-cancerous events may cause
changes in the levels of biomolecules [32]. Blood-based
biomarkers are especially dynamic and can be affected
by the time of sampling, patient diet, level of physical ac-
tivity, medication, and other biological variances, which
are extremely difficult to take into account [33]. Further-
more, the serum/plasma may be considered a difficult
starting material for marker discovery as cancer-related
macro-molecules will be highly diluted and buried in a
complex serum/plasma secretome [34, 35].
In recent years, the importance of the tumor micro-
environment has become a central area of cancer re-
search, as multiple studies have shown how cancer cells
modulate the mechanisms of the surrounding stromal
cells in ways that enable the tumor to induce angiogen-
esis, sustain proliferation, and evade immune destruction
[36]. Cross-talk within the tumor stroma is facilitated by
the tumor interstitial fluid (TIF), which forms the inter-
face between circulating body fluids [37]. In the local
tumor environment, stromal cells and tumor cells are
surrounded by TIF, allowing for the secretion and up-
take of ions, miRNAs, proteins, and other signaling mol-
ecules [38, 39]. As a result, TIF is thought to modulate
the epigenetic program of non-malignant cells by tumor
cells and vice versa, demonstrating the importance of
local tumor milieu for cancer progression [40, 41]. In
addition to molecules secreted from tumor and healthy
stromal and epithelial cells, TIF encompasses external-
ized biomolecules from immune cells in the tumor
microenvironment [42]. Tumor immune cell infiltration
has been shown to be central for the prediction of pa-
tient response to treatment and overall survival [2]. The
relationship between lymphocyte infiltration and tumor
progression is multifaceted [43]. A number of studies
have found that a higher degree of CD8+ T lymphocytes
is associated with a better outcome for patients with BC
[43], especially for the TNBC and Her2-enriched sub-
types [44].
In contrast, tumor-infiltrating CD4+ T lymphocytes
have been linked to a poorer overall survival. This may
be related to the expression of PD-L1 (programmed
death-ligand 1) by some populations of tumor-
infiltrating lymphocytes (TILs), as PD-L1 is a major
inhibitor of an anti-tumor immune response [45, 46]. In
accordance, the degree of immune infiltration by PD-
L1+ T lymphocytes was found to be correlated with
large tumors, high-grade tumors, and positive lymph
node status [45, 46]. It should be noted that the role of
PD-L1 in tumor immune escape is complex, with tumor
cells themselves as well as some populations of immune
cells displaying this protein, and contributes to anti-
immunity in a context-dependent manner [47]. Intersti-
tial fluids provide a snapshot of circulating tumor
molecules, as well as immune cell-secreted biomolecules
associated with tumor properties such as growth and re-
sponse to therapy [2, 48]. As the concentration of
cancer-specific biomolecules within the local tumor mi-
lieu is estimated to be 1000–1500 times that of blood,
TIF is a unique resource for BC biomarker identification
and a promising alternative to a highly diluted serum
secretome [37, 38].
In this study, we analyzed a set of secreted miRNAs
from tumor and normal interstitial fluids acquired from
60 women with breast cancer [49]. The availability of
clinicopathological information, including tumor grade,
receptor status, and BC subtypes classification as well as
the characterization of immune infiltration of every bi-
opsy, allowed us to investigate the relationship between
interstitial fluid miRNA levels and patient clinical fea-
tures. We subsequently identified the deregulated gene
targets of IF miRNAs in tumor tissues from the same
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cohort of patients [50]. Integration of miRNA and
mRNA expression data helps to pinpoint the perturbed
pathways responsible for breast cancer progression while
strengthening biomarker selection by utilizing the com-
binatorial power of a bi-molecular expression profile.
Materials and methods
Datasets for analyses
The miRNA and mRNA data analyzed in this study were
retrieved from previously published works. Briefly, inter-
stitial fluids had been extracted from surgically resected
pieces of breast tumor and normal tissue, collected after
mastectomy [49]. The interstitial fluid microRNA dataset
from interstitial fluids had been profiled using TaqMan
Arrays (TLDA, cat# 4444913; Applied Biosystems, Foster
City, CA, USA), as described in [49]. The transcriptome
profiles of corresponding breast tumor biopsies were
profiled using SurePrint G3 Human GE 8x60K one-
color microarrays from Agilent (Agilent Technologies,
Cat. No. G4851A); this dataset is published in [50]. The
total number of interstitial fluid samples was 60 from tu-
mors and 51 from paired normal fluids, while the tissue
mRNA dataset encompassed 96 tumor samples. The two
datasets were partially paired, i.e., they were from the
same cohort of women with breast cancer; however, not
all sample types were available for all patients. For spe-
cifics on sample collection, storage, preparation, array
types, and protocol, please refer to the primary publica-
tions [49, 50].
Normalization and filtering of tumor interstitial fluid
microRNAs
Data were normalized per sample using global
normalization, and the abundance of each microRNA
was mean-centered. Before analysis, the three samples
with technical replicates were averaged. Next, filtering
was performed to remove samples with tumor percent-
ages ≤ 40%. In addition, samples with low tumor per-
centages and one apocrine tumor were excluded.
Filtering resulted in the removal of 8 samples (IDs 74,
78, 79, 102, 104, 200, 237, 279). After filtering, the data-
set consisted of 51 normal interstitial fluid samples and
52 tumor interstitial fluid samples stratifying into 23 lu-
minal A types, 10 luminal B, 11 Her2-enriched, and 8
triple-negative breast cancer (TNBC) based at the St.
Gallen criteria [51].
miRNAs presented in only a small subset of fluids
(normal and tumor) were removed. A minimum of 8
TIF samples had to contain a given miRNA, at a level
above zero, in order for the miRNA to be retained. The
reasoning behind this filtering approach is that some
miRNAs may be subtype-specific. Often, a threshold is
set so that the minimum of samples containing a given
feature corresponds to the size of the smallest group
used for comparison (TNBC subtype). Filtering reduced
the number of miRNAs from 754 to 561. After filtering
miRNA, missing values were substituted with the lowest
value observed for a given miRNA over all samples.
Abundance values were log2 transformed to deal with
extreme values. Log2 transformation resulted in the ma-
jority of miRNAs approaching a normal distribution of
abundance values. After log2 transformation, the data
were corrected for batch effects using the ComBat func-
tion from the sva R package [52]. The batch-corrected
data were used only for plotting purposes.
Normalization and filtering solid breast tumor mRNAs
Before analysis, the two samples with technical replicates
were averaged. Next, filtering was performed to remove
samples with tumor percentages ≤ 40%. Filtering resulted
in the removal of 16 samples. After filtering, the dataset
consisted of 80 breast tumor samples stratifying into 35
luminal A types, 11 luminal B, 12 luminal B - Her2-
enriched, 9 Her2, 9 TNBC, and 4 unknown/ambiguous
subtypes.
Data were normalized and filtered in accordance with
the limma guidelines for Single-Channel Agilent Inten-
sity Data (Limma user guide, 15 April 2018, page 112)
[53]. Background correction was performed using the
“normexp” transformation method [53], followed by
between-array normalization of intensities. Only tran-
scripts where nine samples (number of samples in the
Her2 group) expressed values above the background
level (gIsWellAboveBG) were retained. Filtering reduced
the dataset from 62,976 transcripts to a total of 32,767
genes.
Multidimensional scaling
Classical multidimensional scaling (MDS) (R version
3.3.1) was used for dimensionality reduction of the two
datasets: (I) miRNA from interstitial fluids and (II)
mRNAs from tumor tissue. MDS was performed with
the function cmdscale, using Euclidean distance as the
distance metric. The plotting was done with R-package
ggplot2 2.2.1 [54]. As the mRNA samples displayed
strong array-related batch effects, these data were cor-
rected with Combat [52] before clustering.
K-means and hierarchical clustering
Prior to clustering, the R package Clusgap [55] was used
to estimate the optimal number of clusters (k) for k-
means. Clusgap implements the gap statistic, which is a
measure of the intra-cluster sum of squares (log (Wk)),
or “compactness” of a given clustering [56]. By compar-
ing the pooled within-cluster sum of squares to a null
reference distribution, with no obvious clustering, Clus-
gap predicts an optimal k—the value for which log (Wk)
is minimized compared to the reference distribution.
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Reference datasets are generated through bootstrapping
by sampling randomly with replacement from the ori-
ginal dataset. For the present analysis, a default of 500
bootstraps was used for sampling [55, 56].
Agglomerative hierarchical clustering was performed
using the squared Ward distance metric [57].
Differential abundance analysis of interstitial fluid
microRNAs and tumor transcriptome
Differential expression analysis (DEA) was performed
using the statistical software limma (linear models for
microarray data) [53] implemented in R. limma has few
underlying statistical assumptions and is known to be
powerful for small sample sizes as a result of shrinkage
of feature-specific variances [53]. An interstitial fluid
miRNA or solid tissue mRNA was considered differen-
tially expressed if the log2 fold change (LogFC) ≥ 1 or ≤
− 1 and the corrected p value (FDR) ≤ 0.05.
Differential expression was carried out using the fol-
lowing group comparisons for both datasets: (I) all pair-
wise subtype combinations, (II) hormone receptor status
(ER, PgR, Her2), (III) high TIL status (+ 2|+ 3) vs low
TIL status (0|+ 1) and (IV) high-grade tumors (gr 3) vs
low/medium-grade tumors (gr 1/2), and (V) K-means
clusters.
Additionally, a contrast of (VI) tumor interstitial fluids
vs normal interstitial fluids was performed for the
miRNA set—this was not possible for the solid tissue
mRNA, as no normal tissue counterparts had been pro-
filed for mRNA.
As clustering analysis had revealed confounding of
tumor immune infiltration scores, tumor grades, and
hormone receptor statuses, we tried de-convoluting dif-
ferentially expressed miRNAs/mRNAs from each con-
trast by including the other covariates in the design
matrix.
In the comparison of TIF vs NIF miRNAs abundance,
we added information on sample ID to account for pa-
tient tumor heterogeneity. For tumor tissue mRNA con-
trasts, information on sample array was incorporated
into the design matrix to account for this technical vari-
ance (batch effect).
MicroRNA families
Information on miRNA families were obtained from
TargetScan v7.2 (http://www.targetscan.org/cgi-bin/tar-
getscan/data_download.vert72.cgi) [58]. miRNA sets
from differential abundance analysis (DAA) were inte-
grated with this information in order to identify overrep-
resented miRNA families in each set. As very few
miRNAs belonged to each miRNA family, regardless of
set, we had very low power. As a result of this, we did
not perform an enrichment test; instead, the number of
miRNAs from each set belonging to a specific family
were scaled according to the set size and visualized in a
tile plot for visual inspection.
Weighted gene co-expression network analysis (WGCNA)
The WGCNA package in R was used to define co-
expression modules [59], consisting of genes, or miR-
NAs, with similar expression patterns. The input of this
analysis was the normalized mRNA expression matrix.
In the first step, correlations were calculated using the
biweight midcorrelation, and a signed weighted correl-
ation network was used to identify co-expression mod-
ules with high topological overlap (TO). Modules were
defined as branches of a hierarchical cluster tree using
the top-down dynamic tree cut method [59]. The ex-
pression patterns of each module were summarized by
the module eigengene (ME), defined as the first principal
component of a given module. Pairs of modules with
high module eigengene correlations (r > 0.9) were
merged. A weighted signed network was computed
based on a fit to the scale-free topology. A thresholding
power of 9 was chosen (the lowest threshold resulting in
a scale-free R2 fit of 0.85), and the pairwise TO between
genes was calculated, which converted pairwise correl-
ation values [− 1,1] to TO co-expression values [0,1]
where values close to 1 represented highly shared co-
expression neighborhoods. The TO dendrogram was
used to define modules using the dynamic tree cut
method function in WGCNA [59] with a minimum
module size set to 40 genes, deepSplit parameter set to 2
and cutHeight set to 0.99. We used the intramodular-
Connectivity function from WGCNA to identify module
hub genes of interest. This function takes as input the
adjacency matrix and the module assignment (i.e., color
assignment), giving as the output a measure of intra-
modular degree. The intramodularConnectivity function
computes the whole network connectivity kTotal, the
within-module connectivity kWithin, kOut = kTotal-
kWithin, and kDiff = kWithin-kOut.
Paired differentially expressed miRNA and mRNA gene
target networks
miRNA target prediction was performed with TargetScan
v7.2 [58], using the predicted (conserved) targets of miRNA
families (http://www.targetscan.org/vert_72/docs/help.html).
Differentially expressed miRNA-mRNA interaction pairs,
with opposite expression directionality, were extracted for
network construction. In addition to miRNA-mRNA pairs,
known direct protein-protein interactions were included
from the InBio Map database (https://www.intomics.com/
inbio/map.html#downloads) [60], we included mRNA-
mRNA (protein-protein) interaction pairs if both mRNAs
were differentially expressed in the same comparison.
Terkelsen et al. Breast Cancer Research           (2020) 22:73 Page 5 of 36
Comparison with cancer miRNA databases
Three databases of cancer-related miRNAs were down-
loaded and curated for comparison in spring 2019: (I)
CMEP (Circulating MicroRNA Expression Profiling),
http://syslab5.nchu.edu.tw/CMEP/ [61], (II) dbDEMC
database of Differentially Expressed miRNAs in human
Cancers, http://www.picb.ac.cn/dbDEMC/ [62]; and (III)
miRCancer (microRNA Cancer Association Database),
http://mircancer.ecu.edu/download.jsp [63]. Information
obtained from each of these databases was as follows:
(I). CMEP: the database contains expression levels of
miRNAs identified in either blood, serum, or
plasma. At the time of download, this database
contained 66 cancer studies on circulating miRNAs.
(II).dbDEMC: the database contains miRNAs known to
be associated with cancer, based on high-
throughput analysis of 209 datasets, from 36 differ-
ent cancer types and 73 subtypes. miRNAs from
this database were quantified from solid tissues,
blood, plasma, and serum. At the time of download,
2224 differentially expressed miRNAs were anno-
tated in dbDEMC.
(III).miRCancer: the database contains intracellular
miRNA expression profiles from various types of
cancers based on PubMed text mining (5700
published studies). At the time of download,
miRCancer encompassed 57,984 miRNAs from 196
cancer types, out of which 7325 were identified as
differentially expressed.
All miRNAs associated with breast cancer were ex-
tracted from the three databases, along with the informa-
tion on the study design, tissue type, and directionality in
sample group comparison. MicroRNAs from databases
were overlapped with the consensus sets from the TIF
miRNA comparisons listed in the “Materials and
methods” section. Only miRNAs which were denoted as
having the same directionality in a study design compar-
able to that of the contrast performed our study were kept
in the final table. As no miRNAs from the databases were
assigned to cancer immune profile, we performed a litera-
ture search to obtain a set of comprehensive reviews on
immune-related miRNAs, subsequently concatenating
these into a list for comparison [64–66].
Support for miRNA-mRNA pairs
MiRTarBase [67] was used to support TargetScan-
predicted miRNA-mRNA pairs. MiRTarBase release 7.0
was downloaded from http://mirtarbase.mbc.nctu.edu.tw/
php/download.php. In addition, we supported pairs using
a consensus approach, in which we overlapped TargetScan
predictions with those from other tools, including
DIANA-microT (thermodynamics) [68], miRBridge
(complementary, conservation, thermodynamics) [69],
PicTar (thermodynamics) [70], PITA (conservation, ther-
modynamics) [71], rna22 (complementary, conservation)
[72], and mirDB (support vector machine) [73]. At least
three tools in addition to TargetScan had to return a
miRNA-mRNA pair in order for this interaction to be
considered “supported.” Methods were implemented
though the meta-tool miRsystem [74], except for the re-
sults from mirDB, which were added subsequently.
COSMIC and CancerMine—oncogenes, tumor
suppressors, mutational burden, and copy number
variations
We employed the COSMIC database [75] and the text
mining tool CancerMine [76] to obtain information
about differentially co-expressed genes from networks
(downloaded: 05-01-2019). Information from COSMIC
included (i) single nucleotide polymorphisms (SNPs)
within the coding region of genes, annotated as patho-
genic by fathmm (Functional Analysis through Hidden
Markov Models, v2.3) [77]; (ii) the COSMIC set of quan-
tified copy number variations encompassing whole genes
(loss or gain) in breast cancer; and (iii) the COSMIC
census set of oncogenes, tumor suppressors genes
(TSGs), and dual role genes (DRGs). Additionally, we
downloaded genes annotated as oncogenes, TSGs, or
driver genes from CancerMine (text mining), both those
related to BC, as well as other types of cancer. For the
CancerMine dataset, we imposed a cutoff of minimum
five citations for any given BC-related gene (75% quan-
tile), while we required at least 12 citations for a non-
BC-associated gene to remain in the dataset (90% quan-
tile). Genes from networks were ranked number of copy
number variations (loss, gain, and total CNVs were
ranked separately) and on mutational burden, here de-
noted as the number of predicted pathogenic SNPs
within the coding region of a gene. All ranks were com-
bined into one final rank for each gene.
To assess a potential enrichment of oncogenes, TSGs,
etc. within gene co-expression modules, we performed
module-wise Fisher’s exact tests (R-base), with correc-
tion for multiple testing using the Benjamini-Hochberg
method.
PubMed search
General terms; [breast cancer], [miRNA/microRNA],
[circulating/blood/serum/plasma].
(V1) terms; [aggressive, aggressiveness, metastasis,
metastatic, prognosis, prognostic, invasive, invasiveness,
survival].
(V2) terms; [subtype, subtypes, luminal, Her2, normal-
like, ER, PgR, estrogen, progesterone, pam50,
immunohistochemistry].
Terkelsen et al. Breast Cancer Research           (2020) 22:73 Page 6 of 36
Results
K-means clustering and dimensionality reduction
captured a TNBC profile, tumor grade, and immune
infiltration
To investigate whether miRNA abundance patterns
could partition NIF and TIF samples, as well as TIF
samples from BC patients with different clinical and
histological traits, we performed clustering analysis and
dimensionality reduction for visualization purposes.
Table 1 shows a summary of the sample metadata.
Multidimensional scaling of tumor and normal inter-
stitial miRNA abundance revealed a distinct clustering
of the 51 NIF and 52 TIF samples. The first component
(M1) highlighted the difference between normal and
tumor, while the second component (M2) captured two
clusters containing a mix of TIF and NIF samples, Add-
itional file 1: Fig. S1A.
A look into sample IDs revealed that the clustering
was most likely driven by patient heterogeneity, a result
of a large fraction of samples being paired. As a control
for this, we treated “patient” as a covariate and removed
this effect, see Additional file 1: Fig. S1B. This correction
unified the NIF samples; however, the tumor samples
continuously formed two clusters, indicating that TIF
sample sub-grouping was driven by similarities between
these patients and not merely by overall patient
heterogeneity.
As seen in Fig. 1a, miRNA profiles of TIF samples be-
longing to cluster 1 were predominantly from patients
with high-grade (grade 3), high-TIL (tumor-infiltrating
lymphocytes, + 2|+ 3) tumors, the majority of which
were estrogen- and/or progesterone-receptor negative.
In quantitative terms, 75% of samples in cluster 1 were
annotated as high grade/TILs. In comparison, TIF clus-
ter 2 was mainly populated by hormone receptor-
positive samples with lower grade (grade 1|2) and low
TIL scores (TILs 0|+ 1), even though this pattern was
less clear than that observed for cluster 1 (62% of sam-
ples were low grade/TILs). The correlation of tumor
grade and TIL score, albeit not perfect, indicated that
tumor interstitial miRNA profiles might be associated
with breast cancer progression.
Subsequently, we examined whether mRNA expres-
sion patterns from paired tumor tissues yielded a similar
clustering and partitioning of samples, as the one ob-
served for interstitial fluid miRNAs. K-means (k = 2)
clustering of tumor mRNA data revealed a pattern com-
parable to that of the interstitial fluid miRNAs. Tumor
mRNA cluster 1 encompassed high-tumor grade, high-
TIL samples (89% of high TILs samples and 79% of
high-grade samples), while cluster 2 contained samples
with lower tumor grade and low-TIL statuses (81% of
low TILs samples and 64% of low-grade samples), Fig. 1b.
We observed a significantly better partitioning of
samples into assigned BC subtype at the mRNA level, as
compared to that of TIF miRNA. This was somewhat
expected as subtyping is based on the intracellular level
of specific mRNA transcripts and/or hormone receptors,
Additional file 1: Fig. S1C and S1D. Additional file 2:
Table S1 contains information on which samples were
assigned to which cluster based on TIF miRNA abun-
dances or intra-tumor mRNA expression levels.
Expression profiles associated with estrogen receptor
status, TNBC subtype, and K-means clusters were clear
across TIF miRNA and tissue mRNA datasets
We performed differential abundance|expression ana-
lysis to identify interstitial fluid miRNAs and solid tissue
mRNAs, which were dysregulated in BC samples vs nor-
mal samples, and between different BC subgroups. Based
on the clustering analysis (Fig. 1a, b), we focused on the
following comparisons: (I) TIF vs NIF, (II) BC subtypes,
(III) cluster 1 vs cluster 2, (IV) high TILs vs low TILs,
(V) ER+ vs ER−, (VI) PgR+ vs PgR−, and (VII) high grade
vs low/medium grade. Figure 1c and d depict the results
of differential expression analysis (DEA) for both inter-
stitial fluid miRNAs (Fig. 1c) and solid tissue mRNAs
(Fig. 1d).
miRNAs
Approximately 1/3 of miRNAs from the TIF vs NIF set
were unique to this comparison, i.e., these interstitial
fluid miRNAs may have potentials as BC biomarkers.
Another ~ 2/3 of miRNAs differentially abundant be-
tween TIF and NIF overlapped both with miRNAs from
the TIF cluster 1 vs cluster 2 contrast and the BC sub-
type contrasts. It should be noted all of the miRNAs
from the subtype contrasts were identified between
TNBC and the other three subtypes (luminal A, luminal
B, and Her2-enriched). The 181 miRNAs identified in
the TIF vs NIF comparison, in the subtype comparison
and in the cluster 1 vs cluster 2 comparison, likely re-
flect both a general tumor-specific miRNA pattern, but
also the aggressiveness of particular breast cancer sub-
types. This observation came from the fact that samples
in cluster 1 originated from more advanced tumors
(high-grade, high immune score, hormone receptor-
negative).
Though there was a large overlap between the afore-
mentioned sets, 41 miRNAs were specific to miRNA
cluster 1 vs cluster 2 contrast. There was a large redun-
dancy of miRNAs identified in the contrasts: high TILs
vs low TILs, high grade vs lower grade, ER+ vs ER−, and
PgR+ vs PgR−. MiRNAs, identified as differentially abun-
dant in our analysis, were compared to those obtained in
the study by Halvorsen et al. [49] in Additional file 3:
Fig. S2 A-C.
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Table 1 Sample summary table
Levels Number Percent Sum %
miRNA No 37 26.4 26.4
Yes 103 73.6 100.0
mRNA No 64 45.7 45.7
Yes 76 54.3 100.0
Tumor percentage 40 2 1.4 1.4
60 29 20.7 22.1
80 58 41.4 63.6
N 51 36.4 100.0
Grade 1 5 3.6 3.6
2 46 33.3 36.9
3 36 26.1 63.0
N 51 37.0 100.0
Her2 0 23 16.4 16.4
1+ 18 12.9 29.3
2+ 28 20.0 49.3
3+ 20 14.3 63.6
N 51 36.4 100.0
ER ER− 20 14.3 14.3
ER+ 69 49.3 63.6
N 51 36.4 100.0
PgR PgR− 40 28.6 65.0
PgR+ 49 35.0 36.4
N 51 36.4 100.0
AR AR− 28 20.0 20.0
AR+ 57 40.7 60.7
N 51 39.3 100.0
Sample type Normal 51 36.4 36.4
Tumor 89 63.6 100.0
Subtype Her2-enriched (Her2) 11 7.9 7.9
Luminal A (LumA) 42 30.0 37.9
Luminal B (LumB) 13 9.3 47.1
Luminal B Her2-enriched (LumB-Her2) 13 9.3 56.4
Triple-negative breast cancer (TNBC) 10 7.1 92.9
Normal 51 36.4 100.0
TIL score 0 17 12.1 12.1
1+ 25 17.9 30.0
2+ 30 21.4 51.4
3+ 17 12.1 63.6
N 51 36.4 100.0
Metastasis 0 71 50.7 50.7
1 18 12.9 63.6
N 51 36.4 100.0
All 140 100.0 100.0
The letter N denotes normal samples. miRNA = TIF miRNA data (yes, no); mRNA = tumor tissue mRNA expression data (yes, no); Tumor percentage
= percentage of tumor tissue in sample, tumor grade (1, 2, or 3); Her2 = Her2 receptor status (0, 1, 2, or 3); ER = estrogen receptor status (+, −); PgR =
progesterone receptor status (+, −); AR = androgen receptor status (+, −). Sample type (tumor, normal); subtype –luminal A, luminal B, luminal B, Her2-
enriched, triple-negative breast cancer, or normal. TIL score = tumor-infiltrating lymphocyte score (0, 1, 2, or 3); metastasis—0 is no metastasis and 1 is
metastasis; outcome—patient outcome, where 0 is alive and 1 is deceased. The biological characteristics of all samples used were retrieved from [49, 50]
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mRNAs
The comparison of intra-tumor mRNA expression pat-
terns from BC subtypes yielded ~ 450 differentially
expressed (DE) genes, out of which 3/4 were unique to
the contrast. This was expected, as subtype classification
was based on the staining of hormone receptor expression
at protein level (immunohistochemistry). The mRNAs not
unique to the subtypes contrast nicely overlapped with
those identified as DE in the comparisons of estrogen and
Her2 receptor amplification (+|−) statuses. No mRNAs
were identified as DE between PgR+ and PgR−, perhaps
due to an unbalanced number of samples in each group,
in combination with the correction for multiple covariates
(i.e., loss of power). A total of 297 mRNAs were identified
as differentially expressed between tumor cluster 1 vs
cluster 2. Out of these, about half were unique to the clus-
ter comparison, while the other half overlapped with DE
mRNAs from the high TILs vs low TILs comparison, indi-
cating that these mRNAs may drive the immune-related
profile observed in Fig. 1b. Surprisingly, the set of mRNAs
which were DE between high- and medium/lower-grade
tumors did not overlap the tumor cluster set, and TILs set
but appeared to be unique to this contrast.
Collectively, the analysis resulted in sets of differen-
tially abundant TIF miRNA, and comparison matched
mRNA sets for (I) high TILs vs low TILs, (II) high grade
vs medium/low grade, (III) cluster 1 vs cluster 2, (IV)
ER+ vs ER−, and (V) luminal A|B and Her2 vs TNBC.
Expression sets from clusters (tumor grade, immune
infiltration) were enriched for microRNA families: miR-15,
miR-17, and miR-130
miRNAs with identical seed regions could potentially
bind and silence the same gene targets [29, 78]. Also,
Fig. 1 Sample clustering and results of differential abundance/expression analysis. a, b K-means clustering of tumor interstitial fluid miRNAs (a)
and tissue mRNAs (b). Both sets display two clusters: cluster 1—hormone receptor-negative samples (ER− and PgR−), high grade (grade 3), and
high TILs (T2, T3); cluster 2—hormone receptor-positive samples (ER+, PgR+), lower grade (grades 1 and 2), and low TILs (T0, T1). c, d Differentially
abundant miRNA from normal and tumor interstitial fluids (c) and mRNA from tumor biopsies (d). Upset plots show the set size for each
comparison and redundancy of these miRNAs: up, FDR < 0.05 and logFC > 1; down, FDR < 0.05 and logFC < − 1. Sets: (1) TIF vs NIF, (2) subtypes
(luminal A vs TNBC, luminal B vs TNBC, and Her2 vs TNBC), (3) estrogen positive vs negative tumors, (4) progesterone positive vs negative tumors,
(5) tumor grade 3 vs tumor grade 1/2, and (6) K-means cluster 1 vs cluster 2
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genes with shared functions may have the same miRNA
binding sites, so these can be conjointly regulated by
specific mRNA families [79]. As such, the identification
of miRNA families enriched or depleted in tumor sam-
ples may increase our understanding of which gene
functions and pathways are dysregulated in cancer.
We mapped miRNAs from each DA set to their re-
spective families, highlighting any potential differential
abundance of related miRNAs, see Fig. 2.
Common to the TIF-NIF, subtype, and cluster sets
were miRNAs belonging to the let-7/miR-98 microRNA
family, known to be aberrantly expressed in a range of
cancer types [80] including breast cancer [81, 82]. While
a few miRNA families were generally abundant in all
sets, some were more set-specific. For TIF cluster 1 vs
cluster 2, miRNA members from the miR-15 family
(miR-15, miR-16, miR-195, miR-424, miR-497), miR-17
family (miR-17, miR-20, miR-93, miR-106, miR-519),
and miR-130 family (miR-130, miR-301, miR-454) were
predominant. Collectively, the enrichment of the miRNA
families supports the partitioning of TIF samples into
two clusters, representing differential tumor progression.
While families miR-15, miR-17, and miR-130 were
most prevalent in TIF cluster sets, miR-30 and miR-
200bc were shared between this set and the TIF vs NIF
set. More specific to the TIF vs NIF comparison were
two miR families: miR-25/miR-92 and miR-548ay/559.
The miR-25/miR-92 family members are situated in the
mir106a-363 and mir106b-25 clusters (Chr X and Chr 7,
respectively), paralogs to the polycistronic miRNA clus-
ter mir-17-92, also designated oncomir-1 [83]. miR-25
and miR-92a have been proposed to be negative regula-
tors of tumor cell apoptosis by directly targeting Bim
(Bcl-2-interacting mediator of cell death) [84].
Dataset integration revealed BC-related miRNA-mRNA
interaction pairs related to clinicopathological
information
To further explore the interplay between circulating
miRNAs and their potential intracellular gene targets,
we constructed custom networks from the differential
abundance|expression sets (see the “Materials and
methods” section). Table 2 shows the total number of
identified DA TIF miRNAs and DE intracellular mRNAs
before and after “pairing” into the interaction networks
(direct miRNA target genes + gene partners).
For the genes included in each interaction network, we
extracted information about the frequency of mutation
(SNPs predicted to be pathogenic) and copy number
variations (CNVs) from the COSMIC database [75], as
well as information about the gene role in cancer from
COSMIC (census set) and CancerMine [76]. Genes were
subsequently ranked on these parameters, allowing us to
evaluate the potential known (well-supported) role, or
novelty, of a gene candidate within a (breast) cancer set-
ting—see Additional file 4: Table S2 for all gene-wise
information.
Tumor immune infiltration
Figure 3 shows the interaction network generated from
miRNAs and gene targets differentially expressed in the
comparison of high TILs vs low TILs—network plots for
all other comparisons may be seen in Additional file 5:
Fig. S3. Figure 3 shows that the differentially expressed
mRNAs from high TIL vs low TIL samples were mainly
chemokines, immunoglobulins, and T cell differentiation
antigens, along with other genes related to immune pro-
cesses (BTLA, ITK, ZAP70, SLAMF6/7) [85]. This obser-
vation was confirmed by pathway enrichment analysis,
which returned as top pathways: cytokine-cytokine recep-
tor interaction, chemokine signaling pathway, and NF-
kappa B signaling pathway, both with and without genes
which were DE in cluster 1 vs cluster 2 (e.g., redundancy
removed). The most interconnected gene was LCK,
which is a well-known oncogene in T cell acute lympho-
blastic leukemia supported by COSMIC and Cancer-
Mine, Additional file 4: Table S2. The interconnectivity
of this gene underlined that this miRNA-mRNA network
was associated with tumor immune cell infiltration and
gene expression. While LCK had the highest number of
interactions, the gene with the most miRNA partners
was NEDD4L, which was downregulated in the high TIL
vs low TIL comparison. Interestingly, the NEDD4L gene
had a high rank (nr. 3) based on mutational burden and
CNVs, and this gene has been proposed to be a TSG in
studies on breast and liver cancer [86, 87]. miR-301-3p
was the miRNA from this network with most gene tar-
gets, including NEDD4L, MYT1 (ranked nr. 2 based on
CNVs and SNPs), and ITGA11.
K-means clusters
There was a significant overlap of DE miRNA-mRNA
pairs retained in the high TILs vs low TILs and the cluster
1 vs cluster 2 comparisons. This was not unexpected as
cluster 1 contained high TILs tumors/TIFs, while cluster 2
contained low TILs tumors/TIFs. In accordance with this,
the overlap mainly encompassed immune-related genes,
including chemokines, immunoglobulins, and lymphocyte
antigens [88–90], 45 in total. Additionally, 15 miRNAs
were shared by these two contrasts, here among miR-
301—see Additional file 6: Table S3.
Despite the overlap, some miRNAs and mRNAs were
specific to each comparison, especially for the cluster
set, which was large with many pairs. For the TILs set,
only miR-543 was unique. miR-543 interacts with
LAMP5 (lysosome-associated membrane protein), very
recently shown to be an autophagy suppressor that pro-
tects leukemia fusion oncoproteins, helping these to
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Fig. 2 MicroRNA family enrichment. Sets of differentially abundant miRNA assigned to miRNA families. x-axis = sets of DA interstitial fluid miRNAs. y-axis =
miRNA family. Color = number of miRNAs belonging to a given family in set. Darker color =more miRNAs belonging to this family. Arrows =miRNAs
of interest
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evade degradation [91]. A total of 51 mRNAs and 65 genes
were unique to the cluster 1 vs cluster 2 comparison—Add-
itional file 6: Table S3. Just as for the analysis with TIL
scores, pathway enrichment analysis with miRNA-mRNA
gene pairs DE from the contrast with clusters were
enriched within the cytokine-cytokine receptor interaction
pathway, chemokine signaling pathway, and NF-kappa B
signaling pathway. In addition to this, however, the genes
from the cluster 1 vs cluster 2 comparison were also
enriched within pathways in cancer, indicating that cluster
comparison captured more than the tumor immune signa-
ture. The most interconnected gene in the cluster compari-
son was PARD6B, which had a high ranking based on the
number of copy number gains; however, this gene was not
annotated as an oncogene or TSG, neither the COSMIC
census nor from text mining—Additional file 5: Fig. S3 and
Additional file 4: Table S2. PARD6B was downregulated in
higher-grade, high-TIL, hormone receptor-negative BC
samples. The miRNAs with most gene targets were miR-
494-3p and miR-103a-3p both of which were downregu-
lated in the higher-grade, high-TIL, hormone receptor-
negative samples. miR-494-3p was mainly paired with im-
mune genes (CD3G, CXCL13, CXCR5, KLRC4), some of
which had been annotated as oncogenes in leukemia in-
cluding IGF1 (DRG; pan-cancer), IKZF3 (driver; leukemia),
NABP1 (oncogene; leukemia), and PDGFRA (oncogene;
pan-cancer). miR-103a-3p interacted with genes SEL1L3,
BTLA, LDLRAD2, PDE3B, and PKIA. The network is in
Additional file 5: Fig. S3 A.
Tumor grade
The network of IF miRNAs and mRNAs from the high-
grade (grade 3) vs the lower-grade (grade 1|2) biopsies
was small with only five genes and six miRNAs. Two
Table 2 Summary Table showing number of DE tumor
interstitial fluid miRNAs and mRNAs, before and after pairing
HER2
vs
TNBC
LumA
vs
TNBC
LumB
vs
TNBC
Cluster
1 vs
Cluster
2
ER+
vs
ER-
High
TILs vs
Low
TILs
High Grade
vs Low/
Medium
Grade
DE
miRNAs
90 90 90 245 16 53 17
DE
mRNAs
174 139 184 343 135 257 30
Retained
DE
miRNAs
31 29 31 89 4 17 7
Retained
DE
mRNAs
27 23 34 113 19 65 5
Pairs 88 74 96 412 19 156 9
Fig. 3 miRNA-mRNA interaction plot. Interaction network for DE miRNA-mRNA targets from the comparison of high TILs vs low TILs. The size of a
dot denotes the absolute log2 fold change. Colors refer to the expression directionality, red = upregulated and black = downregulated. Networks
for all comparison may be found in Additional file: Fig. S3
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Table 3 Best supported circulating differentially expressed miRNAs based on overlap with databases (CMEP, dbDEMC and
miRCancer) and miRNA-mRNA interactions networks
miRNA BC vs
Normal
Luminal/
HER2 vs
TNBC
ER+
vs ER-
PgR+ vs
PgR-
High TILs vs
Low TILs
High TILs vs Low TILs & High
Gr vs Low/Medium Gr
High Gr vs Low/
Medium Gr
Metastasis Poor
Outcome
hsa-let-7a-
5p
Up Down . . . . . . .
hsa-let-7f-
5p
Up Down . . . . . . .
hsa-let-7g-
5p
Up Down . . . . . . .
hsa-miR-
103a-3p
Down . . . . Down . . .
hsa-miR-
106a-5p
Up . . . . Up . Up .
hsa-miR-
106b-3p
Up . . . . Up . Up .
hsa-miR-
106b-5p
Up . . . . Up . Up .
hsa-miR-
107
Up Down . . Up Up Up Up .
hsa-miR-
1260a
Up . . . Up Up . Up .
hsa-miR-
127-3p
Up . . . . . . . .
hsa-miR-
136-5p
Down . . . . Down . Down .
hsa-miR-
138-5p
Up . . . Up Up . . .
hsa-miR-
141-3p
Up Down . . Up Up . Up .
hsa-miR-
146a-5p
Up . . . . Down . . .
hsa-miR-
151a-5p
Up . . . . . . . .
hsa-miR-
15b-5p
Up Down . . Up Up . Up .
hsa-miR-
17-5p
Up Down . . Up Up . Up .
hsa-miR-
186-5p
Up . . . Up Up . Up .
hsa-miR-
18a-5p
Up . . . . Up Up . .
hsa-miR-
190b
Up . Up . . Up . . .
hsa-miR-
19b-3p
Up . . . . Up . . .
hsa-miR-
222-3p
Up . . . . Up . . .
hsa-miR-
23a-3p
Up . . . Up Up . . .
hsa-miR-
299-5p
Down . . . Down Down . Down .
hsa-miR-
29b-3p
Up Down . . . . . . .
hsa-miR- Up Down . . Up Up Up Up Up
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Table 3 Best supported circulating differentially expressed miRNAs based on overlap with databases (CMEP, dbDEMC and
miRCancer) and miRNA-mRNA interactions networks (Continued)
miRNA BC vs
Normal
Luminal/
HER2 vs
TNBC
ER+
vs ER-
PgR+ vs
PgR-
High TILs vs
Low TILs
High TILs vs Low TILs & High
Gr vs Low/Medium Gr
High Gr vs Low/
Medium Gr
Metastasis Poor
Outcome
301a-3p
hsa-miR-
30d-5p
Up Down . . . Up . Up .
hsa-miR-
342-3p
Up . Up . . . . . .
hsa-miR-
342-5p
Up . Up . . . . . .
hsa-miR-
34c-5p
Up . . . . . . . .
hsa-miR-
374a-5p
Up . . Down . . . . .
hsa-miR-
376a-3p
Up . . . . Down . . .
hsa-miR-
423-5p
Up . . . . . . . .
hsa-miR-
424-5p
Up . . . . Up . . .
hsa-miR-
454-3p
Up . . . . Up Up Up .
hsa-miR-
494-3p
Down Up . . . Down . Down .
hsa-miR-
518e-3p
Up . Up Down . . . . .
hsa-miR-
520d-3p
Up . . . . . . . .
hsa-miR-
589-5p
Up . . . . . . . .
hsa-miR-
590-3p
Up Down . Down . . . . .
hsa-miR-
638
Up . . Up . . . . .
hsa-miR-
744-3p
Up Down . . . . . . .
hsa-miR-9-
3p
Up Down . . Up . . . .
hsa-miR-
92a-3p
Up . . . . . . . .
hsa-miR-
941
Up . . . . Up Up Up Up
hsa-miR-
10b-5p
. Down . . Up Up . . .
hsa-miR-
140-3p
. Down . Down . . . . .
hsa-miR-
148a-3p
. Down . . Up Up . . Up
hsa-miR-
222-5p
. Down . Down . . . . .
hsa-miR-
452-5p
. Down Down . . . . . .
hsa-miR-
29b-2-5p
. . Up . . . . . .
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Table 3 Best supported circulating differentially expressed miRNAs based on overlap with databases (CMEP, dbDEMC and
miRCancer) and miRNA-mRNA interactions networks (Continued)
miRNA BC vs
Normal
Luminal/
HER2 vs
TNBC
ER+
vs ER-
PgR+ vs
PgR-
High TILs vs
Low TILs
High TILs vs Low TILs & High
Gr vs Low/Medium Gr
High Gr vs Low/
Medium Gr
Metastasis Poor
Outcome
hsa-miR-
32-5p
. . Up . . Up . Up Up
hsa-miR-
922
. . Up Down . . . . .
hsa-miR-
126-3p
. . . Down . . . . .
hsa-miR-
29c-3p
. . . Down . . . . .
hsa-miR-
432-3p
. . . Down . . . . .
hsa-miR-
450b-5p
. . . Down . . . . .
hsa-miR-
629-5p
. . . Down . . . . .
hsa-miR-
10a-5p
. . . . Up Up Up . .
hsa-miR-
129-5p
. . . . Up . . . .
hsa-miR-
149-3p
. . . . Up . . . .
hsa-miR-
182-3p
. . . . Up . . . .
hsa-miR-
19a-3p
. . . . Up Up . . .
hsa-miR-
432-5p
. . . . Up Up . . .
hsa-miR-
720
. . . . Up . . . .
hsa-miR-
130b-3p
. . . . . Up . Up Up
hsa-miR-
130b-5p
. . . . . Up . Up .
hsa-miR-
135a-5p
. . . . . Up . . .
hsa-miR-
16-5p
. . . . . Up . Up .
hsa-miR-
20a-5p
. . . . . Up . . .
hsa-miR-
20b-5p
. . . . . Up . . .
hsa-miR-
301b-3p
. . . . . Up Up Up .
hsa-miR-
30b-5p
. . . . . Up . . .
hsa-miR-
369-3p
. . . . . Down . Down .
hsa-miR-
874
. . . . . Down . . .
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genes BTRC and CHST1 were downregulated in high-
grade tumors and interacted with miRNAs miR-10(a/b)-
3p, miR-107, and miR-301(a/b)-3p, miR-454-3p, respect-
ively. miR-18a-5p was paired with genes: AMIGO1,
KCND3, and SIK3 and was upregulated in grade 3 vs
grade 1|2 tumors. The network is in Additional file 5:
Fig. S3 c.
BC subtypes and estrogen receptor
Networks of differentially abundant IF miRNAs and
mRNAs from the contrasts with Her2-enriched vs
TNBC, luminal A vs TNBC, and luminal B vs TNBC
shared eight gene transcripts. These were: AR (oncogene;
prostate cancer), CERS6, FOXA1 (oncogene; breast and
prostate cancer), GPR160, KIAA1244, KLK5, SPDEF
(DRG; breast, prostate, lung, and colon cancer), and
XBP1 (oncogene; blood, esophageal, and brain cancer),
all of which have been shown to be BC-related and dif-
ferentially expressed between subtypes [92–96]. A total
of 27 miRNAs were shared between the three networks,
not surprising as the set of DE TIF miRNAs identified in
each comparison was almost completely redundant. The
most interconnected miRNAs of these were miR-9-5p,
miR-15b-5p, miR-17-5p, miR-19a-3p, and miR-30d-5p,
downregulated in all three subtypes compared to TNBC.
While some miRNAs and mRNAs were shared by all
three DE networks, some were specific, or partially so, to
each comparison. As expected, the most interconnected
gene in both luminal types compared to TNBC was ESR1
[97] (DRG; breast, liver, nasopharynx, kidney, lung, bone,
endometrial, and prostate cancer), and in addition, genes
KIF3B, KRT4, and NFIB (DRG; breast, lung, glandular,
Fig. 4 Heatmaps of DA miRNA levels in TIF. Heatmaps showing the separation of TIF samples based on the best DE miRNA candidates from
comparison with databases. a TIF vs NIF. b Luminal (a, b), Her2-enriched vs TNBC. c TIL scores. d Tumor grade. Color scale denotes the expression
levels, purple = high expression and yellow = low expression
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Fig. 5 (See legend on next page.)
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leukemia, bone, skin, brain cancer) were shared between
these two networks. KIF3B was upregulated in the luminal
types, while KRT4 and NFIB (gene ranked nr. 1, based on
mutations and CNVs) were downregulated. Specific to the
luminal A comparison was the gene CCND1 (oncogene;
breast and pan-cancer), the second most interconnected
after ESR1 (oncogene; breast and pan-cancer), while
ELOVL6 (oncogene; liver cancer) was the most intercon-
nected unique gene within the luminal B vs TNBC net-
work. Networks are in Additional file 5: Fig. S3 E,F.
For the contrast of Her2-enriched vs TNBC subtypes,
the gene with the most interactions was CPD, closely
followed by genes ERBB2 (oncogene, breast, and pan-
cancer), GRB7 (oncogene; breast cancer), and LASP1
(DRG; liver, esophageal, leukemia, brain, thyroid gland,
lung, and stomach cancer), all of which belong to the
Her2 amplicon (chromosome region 17q-12-21) [98].
These DE genes were ranked highest based on the num-
ber of predicted pathogenic SNPs and CNVs from COS-
MIC datasets. The ER+ vs ER− network had miRNA-
mRNA pairs that overlapped with those from the lu-
minal vs TNBC networks. The most interconnected
genes were ESR1, GATA3 (DRG; breast, stomach, pros-
tate, colorectal, lung cancer), and GREB1, all upregulated
in ER+ samples, while ERBB2 which was downregulated.
Unique to this comparison was miR-32-5p, which was
over-expressed in ER+ vs ER− tumors and the most in-
terconnected miRNA in the network.
Networks may be seen in Additional file 5: Fig. S3 D,
G. Lists of DE mRNAs and interstitial fluid miRNAs
from pairs may be found in Additional file 6: Table S3.2
(common across sets) and Additional file 6: Table S3.1
(unique to sets).
Network analysis resulted in multiple miRNA-mRNA
pairs, where both TIF miRNA and intracellular mRNA
profiles displayed meaningful directionality in accord-
ance with previously published studies and in the con-
text of a given comparison.
Cancer miRNA databases—support for TIF miRNAs as
potential BC biomarkers
Three databases of cancer-related miRNAs were down-
loaded and curated in order to compare and support the
results obtained from the analysis of interstitial fluid
miRNAs. These databases included (I) CMEP [61] (Cir-
culating MicroRNA Expression Profiling), (II) dbDEMC
database of (Differentially Expressed miRNAs in human
Cancers) [62], and (III) miRCancer (microRNA Cancer
Association Database) [63]. Briefly, the CMEP database
contains circulating miRNA from the blood, plasma, and
serum, while the dbDEMC database and miRCancer
contain both circulating and intracellular miRNAs. MiR-
Cancer is based on PubMed text mining (e.g., miRNAs
only have assigned directionality), while CMEP contains
raw data and dbDEMC contains log fold changes of DE
miRNAs. As none of the miRNAs from databases was
assigned to cancer immune profile, we performed a lit-
erature search to obtain a set of comprehensive reviews
on immune-related miRNAs, subsequently concatenat-
ing these into a list for comparison [64–66].
Table 3 shows the best supported differentially abun-
dant interstitial fluid miRNAs from the different com-
parisons. Each miRNA was included in at least one of
the three databases, with a consensus of expression dir-
ectionality, and were among the most interconnected
miRNAs from the custom miRNA-mRNA networks. As
no networks could be constructed for the TIF vs NIF
and PgR+ vs PgR− contrast (see the section above), miR-
NAs from these sets were only supported by overlap
with databases. Figure 4a–d shows the partitioning of
samples based on the top best-supported miRNAs from
comparisons: TIF vs NIF, luminal/Her2-enriched vs
TNBC, high TILs vs low TILs, and high-grade vs low/
medium grade. miRNA candidates from the ER+ vs ER−
comparison were encompassed by the luminal/Her2-
enriched vs TNBC. As seen from the heatmaps in Fig. 4,
there was a good concordance between the expression of
IF miRNAs in the TIF vs NIF, TILs ,and grade compari-
sons (Fig. 4a, c, d). For the luminal/Her2-enriched vs
TNBC, this pattern was poorer with come separation of
luminal from TNBC and Her2-enriched samples, but
not between these two subtypes.
Collectively, the best supported interstitial fluid miR-
NAs, from differential expression analysis, miRNA-
mRNA interaction networks, and miRNA databases (cir-
culating and solid tissue), could partition normal fluids
and tumor fluids from BC patients with different TIL
scores and tumor grade.
(See figure on previous page.)
Fig. 5 Co-abundant miRNA-mRNA pairs. Dot plots showing the differentially co-expressed genes and their predicted co-abundant miRNA regulators, for the
green, yellow, and red modules. Colors: light orange= TIF miRNA upregulated in given comparison, dark blue = TIF miRNA downregulated in given
comparison; N. B genes have the inverse direction of expression as miRNAs. Bar plots relay information about genes extracted from the COSMIC database [75].
Height/shade of the bar indicates gene rank, based on the mutational burden (SNPs classified as pathogenic) and copy number variations (CNVs, grain + loss)
of a gene from breast tumors. Colors of the bars denote if the gene was classified as a BC oncogene, a BC driver gene, a BC tumor suppressor gene, or a BC
dual role gene within the set of COSMIC gene census set [75] and/or from CancerMine [76]. A star means that a gene was annotated in COSMIC or
CancerMine for another cancer than BC, and the color indicates the gene role. Smaller dots adjacent to miRNA name denote miRNA co-abundance modules
(modules 1–3). Shades: black =module 1, green=module 2, and gray =module 3
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Gene co-expression analysis—highly interconnected
genes from modules were lncRNAs
We applied WGCNA to our set of mRNA in order to
uncover genes with similar expression patterns. Sets of
co-expressed genes could have similar functions and
may belong to the same pathways and cascades involved
in the development of breast cancer.
WGCNA analysis of mRNA expression data revealed
31 modules encompassing a different number of genes.
We explored the higher-level organization and the
relationship between these modules by applying hier-
archical clustering, using the correlation of the module
eigengenes as input (distance metric). The resulting
group of modules is sets of positively correlated eigen-
genes, which may serve as the input for future explora-
tory analyses, generating new interesting hypotheses
(Additional file 7: Fig. S4).
Additionally, we performed intramodular connectivity
analysis for each module, which measures how con-
nected, or co-expressed, a given gene is with respect to
Fig. 6 Enrichment of oncogenes, TSGs, and DRGs in modules and PAM50 gene cardinality. a Barplot showing the fraction (pink color) of oncogenes,
tumor suppressor genes, or dual role genes encompassed by co-expression modules. Modules without any annotated cancer genes are not included,
neither is the gray module of genes (genes not found to be co-expressed). Plus signs indicate that a module was significantly enriched for oncogenes,
TSGs, or DRGs, while minus signs indicate that the module was significantly depleted of these. b Tile plot showing the expression cardinality of PAM50
genes from the analysis compared with the literature. Orange (up) and green (down) colors denote the directionality of genes from the literature for
each subtype. Colors dark gray, light gray, and white indicate if a gene was found to be differentially expressed in the current analysis. Light blue and
white show the consensus of expression cardinality for a given PAM50 gene between the literature and current analysis. Dots below the tiles highlight
which of the PAM50 genes are annotated in the COSMIC Cancer Gene Census set and in the CancerMine database (filtered, see the “Materials and
methods” section)
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the other genes within a particular module (Add-
itional file 8: Table S4). Briefly, this analysis showed that
the turquoise and brown modules encompassed genes
with the highest kWithin, which was partially a conse-
quence of the high density of these two networks. Inter-
estingly, several of these genes belonged to a class of
long non-coding RNAs (lncRNAs) with unknown func-
tions. LncRNAs could be important hubs within these
networks, regulating crucial mechanisms (e.g., interac-
tions with proteins or miRNAs), and may be involved in
the pathogenesis of breast cancer. To date, the inference
of the biological roles of lncRNAs in cancer develop-
ment remains a challenge, but increasing attention has
been given to these molecules considered as potential
key players in [99]. Novel computational approaches and
resources are now available to help researchers in the in-
terpretation of the functions of lncRNAs [100–102].
However, many lncRNAs in our results are still poorly
annotated. Future developments in this field will allow
us to understand the pathogenesis of breast cancer in-
volving complex regulatory networks consisting of
lncRNAs, mRNAs, miRNAs, and proteins. In this
context, the knock-down of the lncRNA hubs could po-
tentially have significant effects on the stability of the
modules, resulting in the partial or complete rewiring of
the networks.
Co-expression modules were correlated with subtype,
immune infiltration, and grade
Modules were correlated with clinical features including
hormone receptor status (ER and PgR), BC subtype, im-
mune infiltration scores, tumor grade, and metastasis in-
formation, connecting co-expressed genes with the
clinical metadata, see Additional file 9: Fig. S5.
Out of the 31 modules identified, six were correlated
with the clinical variables. The green and red modules
showed a positive correlation with estrogen receptor sta-
tus/luminal subtypes and a negative correlation with TIF
clusters, respectively, characterized by tumor grades and
TIL scores. Inversely, the yellow, green, and grey60 mod-
ules were positively correlated with TIF clusters, TIL sta-
tus, and tumor grade, respectively, and negatively
correlated with estrogen receptor status/luminal sub-
types. The blue module was positively correlated with
Fig. 7 Oncogenes and tumor suppressors in co-expression modules. Tile plots depicting how many genes within five selected modules had
been annotated as either an oncogene (orange), a tumor suppressor (green), a dual role/mixed role (purple), or a driver/fusion gene (yellow). The
plots contain all genes from modules which were annotated in COSMIC [75] or which met the cutoff for a CancerMine hit [76], as well as all
differentially expressed genes and all genes from miRNA-mRNA interaction networks. a Green module. b Yellow module. c Red module. d Light
cyan module. e Sky blue module. f Blue module. The large number of dual role genes from CancerMine observed in the plots, arise from the fact
that these genes are not curated, and as such have a variety of roles annotated within and between cancers. Additional file 14, Table S6 contains
the number of cancer-related genes within each of the 28 modules (3 modules had no genes with annotation)
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Table 4 Best miRNA and mRNA target candidates. Differentially co-expressed tumor mRNAs from modules and differentially
abundant interstitial fluid miRNAs predicted to interact by at least four of the following tools/databases: TargetScan [58], DIANA-
microT [68], miRBridge [69], PicTar [70], PITA [71], rna22 [72], and mirDB [73]. miRNAs and mRNAs in this table are shown to interact
in Fig. 7
miRNA name Direction miRNA Gene symbol Direction gene
Luminal vs TNBC let-7a-5p
let-7f-5p
let-7 g-5p
miR-9-5p
miR-15b-5p
miR-17-5p
miR-18a-5p
miR-19a-3p
miR-30d-5p
miR-23a-3p
miR-34c-5p
miR-98-5p
miR-107
miR-129-5p
miR-141-3p
miR-148a-3p
miR-221-3p
miR-222-3p
miR-301a-3p
miR-454-3p
Down CCND1
CERS6
ESR1
KIF3B
THSD4
Up
Luminal B vs TNBC miR-10b-5p
miR-19a-3p
miR-23a-3p
miR-30d-5p
miR-31-5p
miR-135a-5p
miR-135b-5p
miR-301a-3p
miR-454-3p
Down CDKN2AIPNL
ELOVL6
EPB41L5
FLOT1
SERINC3
Up
High-grade tumors miR-10a-5p
miR-10b-5p
miR-107
miR-301a-3p
miR-301b-3p
miR-454-3p
Up BTRC
CHST1*
Down
High levels of TILs miR-103a-3p
miR-136-5p
miR-206
miR-146a-5p
miR-299-5p
miR-494-3p
Down BTLA
BCL11B
CD3G
LTB
LAMP3
KLRC4
Up
TNBC and high-grade and high levels of TILs let-7a-5p
let-7c-5p
let-7d-5p
let-7e-5p
let-7f-5p
let-7 g-5p
miR-9-5p
miR-10a-5p
miR-10b-5p
miR-17-5p
miR-18a-5p
miR-19a-3p
miR-19b-3p
miR-20a-5p
miR-20b-5p
miR-23a-3p
miR-23b-3p
miR-27b-3p
miR-29a-3p
miR-29b-3p
miR-30a-5p
Up CGN
DOC2A
FAM134B
GATA3
NKAIN1
NPNT
PARD6B
RERG
RGS22
SLC39A6
SYT9
TPRG1
Down
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tumor grade (and metastasis) only. Based on these
observations, we intersected differentially expressed
mRNAs from each comparison with the respective mod-
ules of interest to see which of these, and how many,
were retained in each module. Additional file 10: Fig. S6
shows the Venn diagrams of each set overlap. We ex-
tracted DE co-expressed genes from the six modules of
interest and visualized these in heatmaps with the rele-
vant clinical information—Additional file 11: Fig. S7. As
seen from the heatmaps in Fig. S7, co-expressed genes
from modules, which were also differentially expressed,
yielded adequate segregation of BC subtypes, estrogen
receptor status, degree of TILs, and, to a lesser extent,
tumor grade.
As we were specifically interested in TIF miRNAs,
which could potentially regulate the expression of
cancer-related genes through intracellular cross-talk, we
extracted the DE miRNA-gene target interactions of
those genes, both DE and co-expressed in the modules
of interest. These miRNA-gene pairs were filtered to
only retain pairs where the miRNA was supported by
one or more databases (see the section above). Overall,
this data “curation” resulted in a small handful of genes
interacting with multiple miRNAs, many of which were
redundant between comparisons. The comparisons with
miRNA-gene pairs from K-means clusters and subtypes
retained most pairs. Genes in these pairs belonged either
to the green module, red module, or yellow module—see
Fig. 5.
Yellow module
The analysis revealed that the yellow module (Fig. 5d)
consisted of a cluster of co-expressed immune system
genes [85, 88–90], regulated by a small set of miRNAs.
Gene targets were upregulated, while all miRNAs were
downregulated in high TILs vs low TILs. Gene tran-
scripts included, ASB2, BCL11B, BTLA, CD3D, CD3G,
CXCL13, CXCR5, FAM65B, IKZF3, IL7R, KCNA3,
KLRC4, LAMP3, and LTB, mainly interacting with miR-
146a-5p and miR-494-3p. We observed miR-146a and
miR-494 to be downregulated in TIFs from high-grade
tumors with high TIL scores. All miRNAs from the
module, except miR-346, were annotated in the CMEP
database as differentially expressed in the blood from BC
patients. miR-103a, miR-494, and miR-369 were down-
regulated in TNBC compared to other subtypes, while
miR-206, miR-299, and miR-874 were downregulated in
relapse, metastasis, and stage 3 vs stage 2 cancers,
Table 4 Best miRNA and mRNA target candidates. Differentially co-expressed tumor mRNAs from modules and differentially
abundant interstitial fluid miRNAs predicted to interact by at least four of the following tools/databases: TargetScan [58], DIANA-
microT [68], miRBridge [69], PicTar [70], PITA [71], rna22 [72], and mirDB [73]. miRNAs and mRNAs in this table are shown to interact
in Fig. 7 (Continued)
miRNA name Direction miRNA Gene symbol Direction gene
miR-30b-5p
miR-30c-5p
miR-30d-5p
miR-31-5p
miR-32-5p
miR-33b-5p
miR-34c-5p
miR-98-5p
miR-125a-5p
miR-106a-5p
miR-106b-5p
miR-130a-3p
miR-130b-3p
miR-135a-5p
miR-138-5p
miR-141-3p
miR-182-5p
miR-186-5p
miR-192-5p
miR-196b-5p
miR-200a-3p
miR-223-3p
miR-301a-3p
miR-301b-3p
miR-330-3p
miR-340-5p
miR-374a-5p
miR-454-3p
Summary table showing the most interesting miRNAs and gene targets for BC classification, based on all analysis. All miRNAs and genes in this table are
differentially abudant and co-abundant in sets, and their interactions are predicted by at least four different tools for miRNA—gene target predictions tools and/
or experimental validation. A single gene, CHST1, denoted by an asterisk was not co-expressed but still included due to interest from the literature search
Terkelsen et al. Breast Cancer Research           (2020) 22:73 Page 22 of 36
respectively. As no serum set from CMEP was specific-
ally related to immune status, we could not perform this
check; however, the directionality of these miRNAs was
somewhat consistent with our results, as high immune
score tumors were mainly high-grade TNBC. A search
through the STRING database [103] with the set of up-
regulated genes, revealed these to form a network, which
was enriched in immune processes and pathways. Out of
the genes within this network, only BCL11B was anno-
tated in the COSMIC census set of genes with known
roles in BC. However, some of the other genes in the
network had been denoted as oncogenes/driver genes in
relation to different blood cancers (leukemia, lymphoma,
or myeloma). This is in line with the fact that these
genes were differentially co-expressed between breast tu-
mors with different levels of immune infiltration.
Red module
The red module (Fig. 5c) contained co-expressed genes
CCNI, CDKN2AIPNL, ELOVL6, EPB41L5, FLOT1, NEU1,
PPM1H, and SERINC3, with miRNA partners almost
equally distributed across these. miR-23a had the highest
number of assigned gene partners, four in total:
CDKN2AIPNL, ELOVL6, NEU1, and SERINC3. A look
into these genes reveals that with the exception of CCNI,
these genes were upregulated in luminal B vs TNBC com-
parison exclusively. Cross-reference of miR-23a with the
CMEP database of circulating miRNAs showed this
miRNA to be differentially expressed in the blood from
patients with Her2-enriched cancers compared to TNBC.
STRING enrichment analysis of the red co-expression
module revealed genes ELOVL6, NEU1, and SERINC3 to
belong to the sphingolipid metabolic process.
The genes in this network were not well-annotated in
terms of their role in breast cancer. However, EPB41L5
and SERINC3 had a high rank based on mutational bur-
den and CNVs, ELOVL6 was annotated as an oncogene
in prostate cancer, and PPM1H has been proposed to be
an oncogene, due to its relation to PPM1D (a well-
studied oncogene in breast, ovarian, and brain cancers).
Green module
Co-expressed genes from this module and the miRNAs
that regulate them were confounded, on the one hand
originating from the high-grade vs high-TIL set and
from the comparison of TNBC vs other subtypes. This is
supported by Fig. 5, as many miRNAs that were upregu-
lated in the comparison of high TILs|grade vs low TILs|-
grade (Fig. 5a) were, inversely, downregulated in the
luminal/Her2 vs TNBC comparison (Fig. 5b). Co-
expressed gene transcripts in this module, associated
with the luminal vs TNBC set, were C6orf211, CCND1,
CERS6, ESR1, and THSD4. Enrichment and pathway
analysis of the full set of genes related to BC subtypes
revealed that four of these CERS6, ELOVL6, NEU1, and
SERINC3 were involved in sphingolipid metabolism,
whereas C6orf211 (ARMT1), CCND1, and ESR1 were an-
notated in the breast cancer KEGG pathway.
Co-expressed DE gene transcripts from the green
module associated with TIF miRNAs from the TILs/
tumor-grade comparison were BTRC CGN, DOC2A,
ESR1, FAM134B, GATA3, KCNE4, NEDD4L, NKAIN1,
NPNT, PARD6B, RERG, RGS22, SIAH2, SLC39A6, SYT9,
and TPRG1. This set of co-expressed genes were regu-
lated by a range of TIF miRNAs, most of which paired
with between 2 and 3 genes each, with miR-340-5p as
the only miRNA interacting with four transcripts:
NKAIN1, NPNT, RERG, and SIAH2. Other miRNAs of
interest included members of the miR-30 family, regulat-
ing thee mRNAs: DOC2A, SIAH2, and TPRG1. Enrich-
ment analysis and literature search using the STRING
database [103] highlighted the fact that this set of genes
captured both differences between luminal subtypes and
TNBC as well as between high and low tumor grade and
tumor invasiveness. Genes C6orf211, ESR1, GATA3,
NPNT, RERG, SLC39A6, and TPRG1 have all been
linked with estrogen-positive breast cancers and have
been proposed to be part of a prognostic luminal signa-
ture [104]. Some genes in this module were connected
by processes proposed to be involved in tumor progres-
sion, such as DOC2A, CGN (Cingulin), PARD6B,
NEDD4L, and SYT9 which belonged to the KEGG path-
way, tight junction (TJ) (hsa04530), and GEO term, cell
junctions (GO:0030054). These genes were downregu-
lated in high TILs|grade tumors (cluster 1). Another
gene of interest was BTRC, encoding β-transducin
repeat-containing E3 ubiquitin protein ligase (β-TrCP).
Noteworthy was that a handful of genes from this net-
work had been annotated as TSGs either specifically in
relation to breast cancer (GATA3, RERG, and SIAH2)
or in other types of cancer (DOC2A and RGS22). In ac-
cordance, genes from this network were all downregu-
lated in high-grade, high-TIL, TNBC samples.
To identify the best differentially co-abundant
miRNA-mRNA pairs, we also applied weighted co-
expression network analysis to the TIF miRNA dataset.
The analysis returned three co-expression modules
(blue, turquoise, and red), each encompassing around 1/
3 of the miRNAs—Additional file 12: Fig. S8.
The blue and red modules contained miRNAs upregu-
lated in TIFs from high-grade, high-TIL, TNBC tumors
(e.g., up in cluster 1 vs cluster 2). In accordance with
this, miRNAs predicted to be downregulated in fluids
from PgR+ vs PgR− tumor were almost exclusively found
within this module. The main difference between these
two modules was that the red module seemed to capture
the miRNAs, which were only found to be DA in K-
means clusters, not in direct comparisons of TIL status
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or tumor grade. The slightly smaller turquoise module
contained miRNAs downregulated in high-grade, high-
immune score tumors—Additional file 12: Fig. S8. miR-
NAs, which were co-abundant and found to interact
with co-expressed genes, may be seen in Fig. 5.
DA miRNAs with predicted mRNA targets from inter-
action networks and WCGNA, supported by cancer
miRNA databases, may be found in Additional file 13:
Table S5. WGCNA resulted in subsets of co-expressed
genes with accompanying miRNA regulators.
Known tumor suppressors and oncogenes were
predominant within modules correlated with
clinicopathological information
As only a few genes from the best miRNA-mRNA inter-
action pairs were annotated as oncogenes or TSGs, we
explored which known (breast) cancer-related genes
were co-expressed alongside these within modules. The
intersection of co-expression modules with COSMIC
census genes and CancerMine genes (with lower cutoff,
see the “Materials and methods” section) revealed that
while oncogenes and TSGs were equally prevalent within
models, e.g., modules were not enriched in one vs an-
other type of gene, there was a difference in the distribu-
tion of these genes across modules.
We performed enrichment analysis to examine the de-
pletion or enrichment of annotated genes for all mod-
ules. The analysis revealed that seven modules (black,
blue, dark turquoise, sky blue, light cyan, white, and yel-
low) were enriched for genes annotated as oncogenes,
TSGs, or DRGs, while two modules (turquoise and
brown) were depleted of these types of genes, Fig. 6a.
Interestingly, the turquoise and brown modules were
also not correlated with any clinicopathological informa-
tion (Additional file 9: Fig. S5), and in fact, the intra-
modular connectivity analysis had revealed that these
two modules were enriched in highly interconnected
LncRNAs (Section 3.6). The blue module, which was
highly correlated with breast cancer grade and metasta-
sis (Additional file 9: Fig. S5), encompassed most key
breast cancer oncogenes and TSGs, including APO-
BEC3B, BARD1, BRCA1, BRCA2, BRIP1, CHEK2,
DNMT1, EZH2, MAP 3 K13, NF2, POLQ, PPM1D, and
TRIM24. The yellow and light cyan modules also con-
tained some well-annotated BC-related genes, such as
CASP8, FBLN2, FOXO1, PPARG, and SOCS1. We inter-
sected lists of cancer-related genes from modules with
information about whether genes were found to be dif-
ferentially expressed in any comparison and whether
they were included in a miRNA-mRNA network. As was
already known from the analysis performed in the “Co-
expression modules were correlated with subtype, im-
mune infiltration, and grade” section, mainly the yellow
module, out of those enriched for oncogenes and TSGs,
encompassed DE genes. The green, red, and grey60
modules, which were correlated with patient information
and contained DE genes, were also enriched in cancer-
related genes, although this enrichment was not signifi-
cant after correction for multiple testing (odds ratios,
1.41, 1.22, and 1.91). Among highly annotated BC onco-
genes and TSGs in these modules were CCND1, ESR1,
GATA3, SLC9A3R1, SMAD4, STAT3, and KLF5.
Interestingly, some genes known to be key players in
cancer, here among MAP 3K1|MAP 2K4, NOTCH1|-
NOTCH3, PIK3CA, SYK, FOXP1, and TP53, were not
retained in any co-expression module, e.g., they were
encompassed by the gray portion in Additional file 9:
Fig. S5. Additional file 8: Table S4 contains for each
module information about which genes have been anno-
tated as oncogenes, TSGs, DRGs, or driver/fusion genes
in (breast) cancer, and whether the gene was differen-
tially expressed and included in a miRNA-mRNA net-
work. Figure 7 shows which oncogenes and tumor
suppressors were co-expressed in the green, yellow, red,
light cyan, sky blue, and blue modules.
Next, we looked at which genes from each module
were most interconnected, and whether these had been
annotated as oncogenes or TSGs (Additional file 8:
Table S4 and Fig. 7). Only two modules, the light cyan
and sky blue, had an annotated gene, as the topmost in-
terconnected (CAV1 and PDGFRA, respectively), both
of which were differentially expressed. Some modules
did have (breast) cancer oncogenes and TSGs which
were among the top 1% most interconnected, including
the blue module (POLQ, rank nr. 3, not DE), green
module (ESR1, rank nr. 4), and yellow module (PTPRC,
rank nr. 2). Collectively, combining information from
COSMIC and CancerMine, with results of DE analysis,
network analysis, and WGCNA, confirmed that genes
from the green module were specifically related to breast
cancer subtype (ER, PGR, and Her2 status), which genes
in the yellow module represented tumor immune infil-
tration (hub gene PTPRC is a tumor suppressor in T cell
acute lymphoblastic leukemia), while genes in the blue
module were related to progression and metastasis.
Due to the lack of gene expression data from paired
normal samples, we were unable to directly compare the
expression directionality of known oncogenes and TSGs
with expression profiles observed in our analysis. In-
stead, we looked at the cardinality of the PAM50 genes
(some annotated as oncogenes, TSGs, or DRGs), be-
tween subtypes in our analysis, with their known cardin-
ality from literature. Only eight PAM50 genes were
significantly DE between subtypes in our analysis. How-
ever, if we performed DEA without correction for covar-
iates, such as the level of immune infiltration, this
number rose to 33 PAM50 genes, indicating that the
lack of PAM50 genes in the corrected DE sets, was
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mainly a result of low power, perhaps in combination
with differences between the TNBC subtypes and basal-
like cancers. Figure 6b shows that the expression direc-
tionality of PAM50 genes was in consensus with that of
the literature and their potential role in (breast) cancer
[105–107]. Eleven PAM50 genes had been annotated in
the COSMIC cancer gene census, out of which seven
(BCL2, CCNE1, EGFR, ERBB2, ESR1, FOXA1, and
FOXC1) were found to be DE in our analysis, all with a
consensus of cardinality between subtypes—Fig. 6b.
Computational support for miRNA-gene pairs
Finally, we looked into whether miRNA-gene pairs were
supported, either by miRNA gene target prediction tools
and databases, other than TargetScan [58], or by experi-
mental data. We only considered interactions included
in Fig. 5, e.g., the best pairs from combined analyses. Ex-
perimentally, validated pairs were obtained from the
miRTarBase [67]; however, unfortunately, the miRTar-
Base database only supported interactions of very well-
studied genes and miRNAs such as members of the
OncomiR-1 cluster, miR-let-7 family, and genes CCND1,
ESR1, and PARD6B. We, therefore, used alternative
databases and prediction tools to support TargetScan in-
teractions, requiring that at least three additional
methods agreed on a miRNA-mRNA pair. Prediction
tools included DIANA-microT (Thermodynamics) [68],
miRBridge (complementary, conservation, thermody-
namics) [69], PicTar (thermodynamics) [70], PITA (ther-
modynamics, conservation) [71], rna22 (complementary,
conservation) [72], and mirDB (support vector machine)
[73]. Results may be found in Table 4.
Discussion
In this study, we integrated interstitial fluid miRNA
abundances with expression levels of mRNA from paired
tumor tissues. Our analysis allowed us to explore
whether miRNAs secreted into the interstitium could be
associated with differentially expressed gene targets and
whether these targets were co-expressed and/or co-
regulated. We partitioned the data based on sample mo-
lecular and clinical information to obtain sets of differ-
entially expressed IF miRNA and their intracellular gene
targets, hereby elucidating potential pathways and mech-
anisms underlying breast cancer.
As expected, we observed a good separation of BC
subtypes based on intracellular mRNA expression; how-
ever, this was not the case for the interstitial fluid miR-
NAs. Although we did see some clustering of TIF from
TNBC samples, this could just as well be related to the
common higher immune status and higher tumor grades
of these samples [50]. Other studies on circulating
miRNA expression in BC patients have found similar
trends, with a poor distinction of different subtypes,
except for TNBC (or basal-like) tumors [108–110]. The
majority of differentially abundant interstitial fluid miR-
NAs identified in our study were DE in the contrast of
normal vs cancer or associated with immune infiltration
and tumor grade. These results are in accordance with
previously published literature on circulating miRNA BC
from the serum/plasma, as these most often highlight
miRNA profiles related to cancer progression, invasive-
ness, metastasis, and relapse [111–114]. In more quanti-
tative measures, this is supported by a PubMed search
on titles and abstracts (the “Materials and methods” sec-
tion). A search on terms related to circulating miRNAs
+ cancer progression yielded 757 results (18 titles),
whereas the search with terms circulating miRNAs +
subtype only returned 106 results (four titles). A further
look into the four articles with subtype terms in the title
revealed none of them to find differences between
PAM50 or immunohistochemistry subtypes.
When comparing the results of our miRNA analysis to
those obtained in the original study by Halvorsen et al.
[49], results were highly variable. We hypothesize that
discrepancies mainly arise from the following:
 Choice of statistical framework. limma [53], which
was employed in our analysis, is likely to return a
larger number of significant DA miRNAs, compared
to the Kruskal-Wallis test used in the original ana-
lysis [49]. This is due to limma’s underlying Bayesian
properties, which help overcome issues relating to
small sample sizes and miRNA-specific variances.
 Correction for batch effects and confounders.
Clustering of datasets revealed significant
confounding of covariates; as such, we incorporated
information on confounders into the design matrix
for generalized linear modeling with limma.
 Integrative analysis. As we performed an integrated
analysis, including co-abundance analysis and col-
lective analysis of both TIF miRNA data and paired
intra-tumor mRNA data, we naturally curated our
results based on miRNA abundances, as well as the
relationship between miRNAs and predicted differ-
entially expressed mRNA targets. As such, we ob-
tained a very different set of miRNA top candidates
for further analysis and validation.
In addition to the aforementioned, other differences
may have contributed to varying results, (i) how compar-
isons were defined, (ii) cutoff for retaining a miRNA in
the dataset, (iii) cutoff for significance (log fold change
was added as a criterion in our analysis), and (iv) missing
value imputation.
We believe that the solid bioinformatic framework and
data integration implemented in our study have resulted
in new and valuable biological insights while highlighting
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the major impact of data correction and choice of statis-
tical set-up has for down-stream results.
Overall, our analysis revealed a set of miRNAs which
were upregulated in tumor interstitial fluids from mainly
TNBC patients with high-grade and high immune infiltra-
tion score tumors. Subsets of these miRNAs were pre-
dicted to have target genes, which were also differentially
expressed in tumors from the same cohort of patients.
Table 4 shows the overall best candidate interstitial fluid
miRNAs and predicted gene targets, based on all analyses
and database support.
In the following sections, we will discuss some of these
most interesting miRNAs and genes, in greater detail.
Breast cancer subtypes
Common to subtypes
The most interconnected DE miRNAs from the compar-
isons of BC subtypes were miR-9, miR-15b, miR-17,
miR-19a, and miR-30d. We found these to be depleted
in tumor interstitial fluids from patients with luminal
and Her2-enriched breast cancers, compared to samples
from TNBC patients. Interestingly, all of these miRNAs
have been shown to be highly abundant in the basal-like
BC subtype, which is largely similar to TNBC [115, 116].
Patients with basal-like/TNBC tumors are known to
have the poorest prognosis, and this subtype is associ-
ated with high-grade and rate of metastasis [8]. In ac-
cordance with this, miR-17 and miR-19a belong to the
miR-17-92 cluster, also denoted OncomiR-1 (13q31.3)
[117]. We found these two miRNAs, along with other
members of OncomiR-1 (miR-19b, miR-18a, and miR-
20a), to be differentially co-expressed. The miR-17-92
cluster of miRNAs has been shown to target the well-
studied tumor-suppressor PTEN (phosphatase and ten-
sin homolog), as well as key players involved in TGF-β
(transforming growth factor beta) signaling [118].
Multiple studies on miR-17 have found an association
between the over-expression of this family of miRNAs
with poor patient prognosis (poor disease-free survival
and overall survival) [119, 120] and, in connection with
this, cancer cell migration and invasion in breast cancer
[121, 122].
Over-expression of miR-30d and miR-9 has been asso-
ciated with an aggressive phenotype, shorter time to re-
currence, and a poor prognosis in patients with breast
cancer [123, 124]. More specifically, miR-30d is pro-
posed to be an inhibitory regulator of autophagy [125],
and the miR-30 family of miRNAs is thought to promote
non-attachment growth of breast cancer cells [126].
MiR-9, miR-15b, miR-17, miR-19a, and miR-30d were
predicted to interact with a set of differentially expressed
genes, some of which were common to the three subtype
comparisons. Common genes were AR (androgen recep-
tor), CERS6 (ceramide synthase 6), FOXA1 (forkhead box
A1), GPR160 (G protein-coupled receptor 160),
KIAA1244 (ARFGEF family member 3), KLK5 (kalli-
krein-related peptidase 5), SPDEF (SAM pointed
domain-containing ETS transcription factor), and XBP1
(X-box binding protein 1), all of which were upregulated
in luminal types and Her2-enriched TIF samples vs
TNBC. Three of these genes belonged to the PAM50
set: AR, FOXA1, and GPR160 [7], while the remaining
genes had all been individually associated with breast
cancer subtypes [92–96].
Luminal subtypes
While some genes were common to the three contrasts,
others were subtype-specific, such as ESR1 (estrogen re-
ceptor 1), KIF3B (kinesin family member 3B), KRT4
(keratin 4), and NFIB (nuclear factor I B), which were
associated with luminal types only. KIF3B was upregu-
lated in the luminal samples, and in accordance with
this, KIF3B has been shown to be over-expressed in ER-
positive tumors, with estrogen directly inducing the ex-
pression of KIF3B [127]. KRT4 and NFIB were downreg-
ulated in luminal subtypes compared to TNBC. KRT4
and NFIB have both been shown to be over-expressed in
basal/TNBC tumors [128, 129], supporting our findings.
The expression levels of keratins change during meta-
static progression of breast cancer, and over-expression
of some keratins have been associated with poor patient
survival [130]. Of particular interest was NFIB, which
has directly been proposed as a potential gene target for
ER-negative breast tumors. NFIB was found to be over-
expressed in TNBC compared to ER-positive tumors,
and over-expression of this gene was associated with a
high nuclear grade [129]. ESR1 and CERS6 (see the sec-
tion above) were co-expressed in the green module,
along with C6orf211 (ARMT1, acidic residue methyl-
transferase 1), CCND1 (cyclin D1), and THSD4 (throm-
bospondin type 1 domain containing 4). This set of genes
has been suggested as markers for a prognostic luminal
signature [104] and has more recently been highlighted
as the key players in a novel, FOXA1/ESR1-interacting
pathway [131], highlighting their association with estro-
gen receptor status.
Luminal A subtype
The gene CCND1 was upregulated and highly intercon-
nected in the luminal A vs TNBC comparison. CCND1
is a well-studied breast cancer driver gene [132], the
amplification of which is more prevalent in luminal sub-
types compared to Her2 and basal-like [133]. Amplifica-
tion of this gene has been found to be more prevalent in
luminal B tumors compared to luminal A [134]. How-
ever, as CCND1 amplification is also associated with a
more aggressive phenotype within both luminal sub-
types, as well as in familial and sporadic tumors [134],
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this might explain the slight discrepancy we observe
here, e.g., different compositions and sizes of luminal
sets, resulting in this gene not reaching significance in
the luminal B vs TNBC comparison. A comparison of
miRNA-gene pairs with MiRTarBase resulted in support
for the CCND1 gene and its predicted miRNA
regulators.
Luminal B subtype
For the contrast of luminal B vs TNBC, the ELOVL6
(ELOVL fatty acid elongase 6) gene was found to be up-
regulated and interact with both a larger number of
genes and miRNAs. A high level of ELOVL6 (oncogene
in prostate cancer) has been proposed to be a marker of
poor prognosis in BC [135], which is of great interest, as
patients with luminal B type tumors generally have
poorer outcomes than those with luminal A types [8].
Dysregulated expression of genes involved in mammary
gland fatty acid and phospholipid metabolism, such as
the ELOVL6 gene, have been proposed to characterize
cell proliferation and differentiation state, and many of
these have been linked to BC patient survival [136].
STRING network analysis with the set of eight co-
expressed from the red module (including ELOVL6),
returned the gene ontology term sphingolipid metabol-
ism. Genes assigned to this term were ELOVL6, NEU1
(neuraminidase 1), and SERINC3 (serine incorporator 3).
A literature search revealed that another gene from this
module, FLOT1 (flotillin), had recently been linked to
the sphingolipid pathway, proposed to be a regulator of
cellular sphingolipid distribution and signaling [137]. All
genes from the red module, except CCN1, were specific-
ally upregulated in luminal B vs TNBC, but not in lu-
minal A type, indicating that over-expression of
sphingolipid-related genes might be specific to luminal B
tumors. Interestingly, ELOVL6, NEU1, and SERINC3
were the predicted targets of miR-23a, which was also
highly interconnected and downregulated in the luminal
B vs TNBC comparison. A literature search for miR-23a
revealed this miRNA to be a well-known oncogenic
miRNA, and a recent study by Ma et al. [138] found that
over-expression of miR-23a induced EMT, migration, in-
vasion, and metastasis of breast cancer both in vitro and
in vivo [138]. miR-23b has been proposed to be a circu-
lating biomarker for BC diagnosis, subtyping, and dis-
ease recurrence [139], many times over, highlighted by a
novel review on this miRNA [140].
Estrogen-positive tumors
The DE expression network generated for ER+ vs ER−
tumors and interstitial fluids showed ESR1, GATA3
(GATA binding protein 3), and GREB1 (growth-regulat-
ing estrogen receptor binding 1) to all be upregulated,
while ERBB2 (Erb-B2 receptor tyrosine kinase 2) was
downregulated. Both GATA3 and GREB1 have been
linked to estrogen receptor-positive breast tumors and
have been proposed as markers for patient response to
hormone treatment [141–143].
The most interesting miRNA from this network was
miR-32-5p, which was over-expressed in ER+ tumors vs
ER− tumors, and the most interconnected miRNA in the
network. Not much is known about this miRNA in con-
nection with breast cancer; interestingly, however, miR-
32-5p interacts with genes NFIB, SOX11 (SRY-box 11),
and DSC2 (desmocollin 2) (downregulated in ER+ vs
ER−), all three of which are known to be over-expressed
in basal-like/TNBC/ER− tumors and associated with
poor survival [129, 144, 145].
Her2-enriched subtype
Specific to the contrast Her2-enriched vs TNBC, were
genes ERBB2, GRB7 (growth factor receptor bound pro-
tein 7) and LASP1 (LIM and SH3 protein 1), all of which
were upregulated. These genes are well-supported cen-
tral players in Her2-enriched cancers and belong to the
Her2 amplicon (chromosome region 17q-12-21) [98].
ERBB2 and GRB7 are both Pam50 genes [7]. Another
gene specific to the Her2 set was CPD, which overall
had the most interactions in the miRNA-mRNA net-
work. CPD (carboxypeptidase D) is another gene known
to be amplified in patients with Her2-enriched tumors
on chromosome 17, right upstream of ERBB2 (chromo-
some region 17q-11-2) [146].
Tumor-infiltrating lymphocyte scores and tumor grade
Analysis of the miRNA-mRNA pairs differentially
expressed in high TILs (2, 3) vs low TILs (0,1) revealed
the NEDD4L (NEDD4 like E3 ubiquitin protein ligase)
gene, to be paired with the highest number of miRNAs.
NEDD4L, which was downregulated in samples with
high tumor-infiltrating lymphocytes scores, has been
shown to be a negative regulator of Wnt-signaling
[147]—a pathway often perturbed in cancer [148]. Wnt
signaling is central in the regulation of immunity and
has been reported to facilitate immune evasion via den-
dritic cells and T regulatory cells [149]. In a study by
Ding et al. [147] on NEDD4L inhibitory effects on the
Wnt signaling, it was noted that NEDD4L is often found
to be downregulated in cancers, while its Wnt-target Dvl
(disheveled), which is modified by NEDD4L for proteaso-
mal degradation, is often upregulated in the same can-
cers [147]. This could indicate that the accumulation of
Dvl contributes to an oncogenic type of Wnt signaling.
Furthermore, the downregulation of NEDD4L has been
implicated in the initiation of breast tumor development,
and this gene has been proposed as a prognostic lung
cancer marker linked to histological grade, tumor stage,
and lymph node metastasis [86, 150]. These findings
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support the results of our analysis, as samples with high
immune scores were also those with a high histological
grade (grade 3 tumors). Additionally, our analysis re-
vealed that NEDD4L interacts with PARD6B (Par-6
family cell polarity regulator beta) and CGN (cingu-
lin). These two genes were co-expressed in the green
module and were downregulated in cluster 1 (high
TILs and high-grade, mainly TNBC) vs cluster 2 (low
TILs and lower grade, mainly luminal). PARD6B,
CGN (cingulin), and NEDD4L belong to the KEGG
pathway, tight junction (TJ) (hsa04530). Aberrant
levels of tight junction proteins result in incorrect
formation and maintenance of cellular polarity,
contact inhibition, and proliferation, contributing to
epithelial-mesenchymal-transition (EMT) [151]. PARD6B
expression is critical for TJ assembly, and decreased ex-
pression of this gene has been proposed to result in epi-
thelial cell changes and tumor metastatic behavior [152].
PARD6B has been shown to be amplified in breast cancer
[153]; however, in a comparison of BC subtypes, the ex-
pression of this protein was specifically proposed to be up-
regulated in the luminal type compared to basal-like and
Her2-enriched tumors [154]. This observation is in ac-
cordance with our findings, as it was had a higher expres-
sion level in cluster 2 than in cluster 1. Although PARD6B
is generally considered to be an oncogene, it has also been
linked to suppression of cell proliferation in breast cancer,
indicating that the role of this gene may be complex [155].
PARD6B, CGN (cingulin), and NEDD4L were all predicted
targets of the OncomiR-1 (13q31.3) cluster, or one of its
paralogues 106a/363 (Xq26.2) and 106b/25 (7q22/1),
miRNA included miR-17, miR-19a/b, miR-20a/a, and
miR-106a/b. In accordance with this, NEDD4L has experi-
mentally been shown to be the gene target of the miR-
106-25 cluster miRNAs [86].
Tumor grade
Network analysis of miRNA-mRNA DE pairs high-grade
tumors (grade 3) vs medium/low-grade tumors (grades
1, 2) revealed two genes of interest. One of these genes,
BTRC (beta-transducin repeat containing E3 ubiquitin
protein ligase) predicted to interact with miR-10a/b and
miR-107. Interestingly, we found these three miRNAs to
be co-abundant (module 1, Fig. 5). One study on
miRNA-10b found that this miRNA was secreted via
exosomes and that the uptake of these exosomes by re-
cipient cells resulted in a decrease of target gene levels
and induced invasiveness in otherwise non-malignant
cells [24]. Whereas miRNA-10b is generally considered
to promote tumor progression and metastasis [156], the
role of miR-107 in breast cancer seems less straightfor-
ward. Some studies suggest that miR-107 has a tumor-
suppressive role [157], while others have found that
over-expression of this miRNA promotes tumor
progression, is associated with lymph node metastasis
and poor patient prognosis [113, 158]. Just as for miR-
107, the role of β-TrCP (encode by BTRC) in cancer de-
velopment and progression is convoluted. BTRC has
been proposed to be a DRG, having oncogenic proper-
ties in one context and anti-tumor functions in another
[159]. More recent literature on β-TrCP, however, sug-
gests that this protein indeed suppressed tumor progres-
sion, as one study showed that β-TrCP regulates the
degradation of CDK1, high levels of which promote cer-
tain aspects of tumor malignancy [160]. Another study
on β-TrCP in glioma found that a low level of this pro-
tein was associated with a poor prognosis [161]. Our re-
sults agree with these studies; we see a downregulation
of BTRC in high-grade tumor tissues and an upregula-
tion of miR-10a, miR-10b, and miR-107 in matched
interstitial fluids of these tumors. Importantly, the inter-
action between miR-10a and the BTRC transcript has
been experimentally validated (luciferase reporter experi-
ment) [162]. Although we could not find any experimen-
tal validation for the BTRC-miR-107 interaction, a study
by Yang et al. [163] found that a combination of miR-
107-BTRC-UBR3-miR-16 expression could distinguish
between different BC subtypes, specifically between
basal-like tumors and luminal types [163].
Another gene of interest in relation to tumor grade
was CHST1 (carbohydrate sulfotransferase 1), which was
paired with miRNAs miR-301a/b and miR-454. Analysis
revealed miR-301a/b and miRNA-454 to be co-abundant
in the same module as miR-10a/b and miR-107 (module
1, 5), supporting the notion that these miRNAs might be
associated with tumor grade and progression. The litera-
ture on CHST1 and cancer is very limited; however,
studies on other members of the carbohydrate sulfo-
transferase (CS) family show that while some CS mem-
bers may be oncogenic, others could have tumor
suppressor functions. Overexpression of CHST3 and
CHST11 have been linked to BC aggressiveness, relapse,
and development of metastasis [164]; in contrast, down-
regulation of CHST10 and CHST14 has been linked to
invasive melanoma and to late stages of colon cancer
progression, respectively [165, 166]. In the current study,
we found CHST1 to be downregulated in grade 3 vs
grade 1|2 tumors. The miRNAs predicted to interact
with CHST1 are more well-studied then their target.
MiR-301 is thought to be a breast cancer oncomiR,
which promotes tumor invasion and nodal or distant re-
lapses via direct interaction with FOXF2, PTEN,
BBC3iso-2, and COL2A1 [167]. This microRNA has also
been shown to help regulate cancer-related immunity in
solid tumors [64]. In accordance with this, we found
miR-301a and miR-301b to be upregulated both in the
contrast of IF from high grade to medium/low grade and
between high TILs and low TILs. High expression of
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miR-454 has been associated with a poor overall and
disease-free survival in patients with TNBC [168]. These
findings were supported by a meta-study by Lu et al.
[169], although this review also highlighted the fact that
miR-454 might have a dual role, exerting oncogenic ef-
fects in some cancer types, such as breast cancer, and
tumor-suppressor functions in other types of cancer
[169].
Tumor-infiltrating lymphocytes
Analyses revealed a set of TIF miRNAs and co-expression
gene targets, which were associated with tumor-
infiltrating lymphocyte scores. This network included
miRNAs; miR-103a, miR-136, miR-146a, miR-299, miR-
301, miR-346, miR-369, and miR-494 predicted to interact
with gene transcripts: ASB2, BCL11B, BTLA, CD3D,
CD3G, CXCL13, CXCR5, FAM65B, IKZF3, IL7R, KCNA3,
KLRC4, LAMP3, and LTB. This set of genes, which were
all upregulated in high-TIL vs low-TIL samples, has all
been linked to immune system processes [170–173].
Genes such as CD3D and CD3G encode T cell surface gly-
coproteins and are well-known players in anti-tumor im-
munity [174]. High levels of these two antigens have been
linked to an overall better prognosis of patients with
breast cancer [175, 176]. The same is true for BCL11B,
IKZF3, and KLRC4, which have very recently been linked
to a prognostic immunogenic signature of triple-negative
breast cancers [173, 177]. Liu et al. [177] found that al-
most all populations of immune cells, immune system
pathways, and their genes were enriched in TNBC com-
pared to both normal samples and other breast cancer
subtypes. This is in accordance with our findings; we see
TNBC having not only overall higher grade but also infil-
trating lymphocyte scores.
Of particular interest was the co-expression of genes:
BTLA, CXCR5, CXCL13, IL7R, LAMP3, and LTB. The
protein products encoded by genes have been linked to
the presence or absence of high endothelial venules and
tertiary lymphoid structures in multiple cancer types
[178–181]. TLS, which are lymphoid formations, have
been found within tumors where they are thought to
participate in anti-tumor responses. A high number of
TLS is generally associated with an overall better pa-
tient’s survival in a range of different types of cancer
[182], and their presence correlates with the level of
both TILs and HEV [179, 180]. These observations are
supported by the fact that high endothelial venules,
which are specialized vessels normally found in the
lymph nodes, are proposed to act as gateways for the in-
filtration of lymphocytes within tumors [183]. The abun-
dance of lymphoid chemokines such as CXCR5 and
CXCL13 has been linked to both the presence of TLS
and HEV in breast cancer stroma [181]. Tertiary lymph-
oid structures are modulated by a network of cytokines,
and the central players in this network are lymphotoxin
LT-β-related cytokines [179]. One study [178] found that
lymphotoxin LT-β was overexpressed in breast tumors
and that overexpression of LT-β was correlated with a
high density of HEVs and dendritic cells. Dendritic cells
are thought responsible for the production of LT-β in
tumor tissues in general and in tertiary lymphoid struc-
tures. These findings might indicate that a high level of
LT-β should be predictive of a better patient outcome.
However, another study on the LT-β network in mice
has shown that high levels of lymphotoxin LT-β pro-
mote a tumor-permissive microenvironment resulting in
tumor progression [184]. The results of our analysis sup-
port those from the aforementioned studies, with this
set of genes found to be upregulated in samples with
high levels of lymphocyte infiltration. For a more in-
depth description of the relationship between TLS, TILs,
and HEV, as well as the roles of BTLA, IL7R, and
LAMP3 in relation to these, we refer to the original pub-
lications [178–180, 184].
The set of co-expressed immune genes discussed
above was mainly predicted to be the targets of miR-
146a and miR-494. We found these miRNAs, along with
miR-206, miR-369, and miR-376a, to be co-abundant
(module 2, Fig. 5). Both miR-146a and miR-494 have
been linked to immune system response in connection
with tumor development [185–188]. miR-146a is a cen-
tral player within the innate immune system, where it
functions as a fine-tuning mechanism, modulating the
scale of immunity vs tolerance [189]. Generally, this
miRNA is considered a negative regulator of immune re-
sponse. This is supported by mouse knock-down experi-
ments, in which loss of miR-146a was shown to result in
autoimmunity and development of myeloid malignancies
[189, 190]. Re-establishing miR-146a expression within
breast cancer has been shown to decrease the levels of
immunostimulatory genes and to antagonize NF-kB sig-
naling, reducing cancer cell migration and metastatic
mechanisms [185, 187]. The role of miR-494 in cancer
immunity is not straightforward. One study found that
this miRNA might help prevent anti-tumor immunity
through the accumulation of myeloid-derived cells in the
microenvironment, promoting tumor growth [186],
while another study showed that miR-494 suppresses the
progression of breast cancer, through downregulation of
CXCR4-mediated oncogenic communication [188]. Al-
though miR-146a and miR-494 had the most gene tar-
gets within the co-expressed immune gene cluster, other
miRNAs were also of interest here among miR-103a,
miR-301, and miR-369 all of which have been linked to
tumor immunity [64, 191]. A search thought the CMEP
database revealed all of these to be DE in the blood of
BC patients. miR-103a, miR-301a, miR-494, and miR-
369 were all downregulated in TNBC compared to other
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subtypes. This is in full accordance with our results, as
high immune score tumors were mainly TNBCs.
Conclusion
We identified genes that were differentially co-expressed
between tumors with high and low infiltrating lympho-
cyte scores—most of these had already been associated
with cancer immunity through other studies [170–173].
Of particular interest were CXCL13, BTLA, IL7R,
LAMP3, and LTB as these genes have been linked to the
presence of tertiary lymphoid structures (TLS) and high
endothelial venules (HEV) within tumors. TIF miR-146a
and miR-494, the most interconnected and co-abundant
miRNAs in this cluster, were both previously annotated
as negative regulators of immune-stimulatory genes and
were DE in the plasma from patients with BC [158, 192].
As tumor immune cell infiltration is highly related to pa-
tient prognosis [2], we propose genes and miRNA from
this module to be candidate markers of tumor immune
status, prognosis, and potentially patient response to
immunotherapy.
Another co-expression module encompassed genes,
which were DE between luminal B tumors and TNBC. A
subset of these was related to sphingolipid metabolism
and predicted to be co-regulated by miR-23a. miR-23a
has been found to be differentially abundant in the
serum of healthy individuals and breast cancer, as well
as between BC patients with different subtypes [140]. As
such, this miRNA is a candidate marker for BC subtype
and potentially a new therapeutic target. TIF miRNAs
DE between subtypes were all identified in contrasts of
TNBC vs another subtype. Many miRNAs identified in
these contrasts were generally related to BC progression
and metastasis, such as members of the OncomiR clus-
ters and miRNA families miR-30 and let-7. This obser-
vation is supported by other studies on secreted
miRNAs, and we therefore propose that levels of se-
creted miRNAs do not reflect gene-based subtyping, but
rather tumor aggressiveness, i.e., TNBC patients often
have higher-grade tumors and a poor prognosis.
A small set of genes and TIF miRNAs were more spe-
cifically associated with tumor grade, here among miR-
10a/b and gene target BTRC. The interaction of miR-10-
BTRC has been experimentally validated [162], and miR-
10b was found to be delivered via exosomes to recipient
cells, resulting in the downregulation of target genes
[24]. BTRC is proposed to have tumor-suppressive func-
tions [160, 161], while miR-10b is oncogenic; as such, it
should be of interest to study this pair in relation to
tumor invasiveness and metastasis.
Collectively, integration of expression data from inter-
stitial fluid miRNAs and paired solid tissue mRNAs re-
sulted in sets of miRNA-mRNA pairs, associated with
underlying molecular mechanisms and clinical features
of breast cancer.
Whether TIF miRNAs highlighted in our study are in-
deed transferred between cells in the tumor microenvir-
onment, or whether these merely reflect that level of
miRNAs within the tumor donor cells themselves, is un-
known. However, as the uptake of miRNAs from the
extracellular space is a well-known phenomenon, com-
munication and transcriptome regulation via interstitial
fluid miRNAs are an attractive therapeutic angle for can-
cer treatment.
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Additional file 1: Figure S1. Multidimensional Scaling Plot. Plot depicts
the relationship (squared euclidian distances) between breast cancer
samples based on the abundance of interstitial fluid miRNA or expression
of intra-tumor mRNA. S1A = clustering based on miRNA abundances in
IFs before correction for patient-specific effects. Colors: grey = normal
interstitial fluids, red = tumor interstitial fluids. S1B = clustering based on
miRNA abundances in IFs after correction for patient specific effects (het-
erogeneity). Colors: grey = normal interstitial fluids, red = tumor intersti-
tial fluids. S1C = clustering based on miRNA abundances in TIFs. Colors
denote BC subtypes: dark green= luminal A, light green = luminal B, pink
= luminal B Her2-enriched, orange = Her2-enriched and deep red =
TNBC. S1D = clustering based on intra-tumor mRNA expression. Colors
denote BC subtypes: dark green= luminal A, light green = luminal B, pink
= luminal B Her2-enriched, orange = Her2-enriched and deep red =
TNBC.
Additional file 2: Table S1. K-means Clusters. Partitioning of samples
into two K-means clusters (C1, C2), based on interstitial fluid miRNA abun-
dances or intra-tumor mRNA expression levels. Dot represents an un-
matched sample. The column “consensus” denotes whether the sample
was assigned to the same cluster based both on miRNA and mRNA
levels.
Additional file 3: Figure S2. Comparison of Differentially Abundant
miRNAs. Comparison of differentially abundant miRNAs from current
analysis with original publication (Halvorsen, et al. 2017). S2A =
Comparison of miRNAs DA in TIF vs NIF, and expressed in paired serum,
set include (i) miRNAs DA between TIF vs NIF, from Halvorsen, et al. 2017,
(ii) miRNAs DA between TIF vs NIF, also in serum, from Halvorsen, et al.
2017, and (iii) miRNAs DA between TIF vs NIF from current analysis. S2B =
Comparison of miRNAs DA between BC subtypes. Sets include (i) miRNAs
DA between subtypes, from Halvorsen, et al. 2017, (ii) miRNAs DA
between subtypes significant after correction for multiple testing, from
Halvorsen, et al. 2017, (iii) miRNAs DA between subtypes significant from
current analysis and (iv) miRNAs DA between ER+ and ER- from current
analysis. S2C = Comparison of miRNAs associated with the degree of
tumor infiltrating lymphocytes. Sets include (i) miRNAs associated with
TILs and tumor percentage, from Halvorsen, et al. 2017, (ii) miRNAs DA
between high (+2|+3) vs low TILs (0/1) from current analysis. (iii) miRNAs
DA between high (gr 3) vs low/medium tumor grade (gr 1|2) from
current analysis, and (iv) miRNAs DA between TIF Cluster 1 vs Cluster 2
from current analysis.
Additional file 4: Table S2. This table contains sets of genes (mRNAs)
from miRNA-mRNA networks, with accompanying information on logFC,
adjusted p-values, information from the COSMIC database about fre-
quency of mutations (predicted to be pathogenic), copy number varia-
tions (loss, gain) and information about known role in cancer.
Additionally the table(s) also contains information about genes from Can-
cerMine text-mining tool, e.g. if a given gene has been referred to as an
oncogene, driver gene or tumour suppressor in literature. Genes are
ranked based on mutational burden and CNVs.
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Additional file 5: Figure S3. miRNA-Gene Interaction Networks. Net-
works of differentially expressed miRNAs and gene targets predicted by
TargetScan. Colors refer to expression directionality, red = up-regulated,
black = down-regulated. S3A = TIF Cluster 1 vs Cluster 2, S3B = High TILs
(+2|+3) vs low TILs (0|+1), S3C = High-grade (gr 3) vs medium/low-grade
(gr 1|2), S3D = Her2 vs TNBC, S3E = luminal A vs TNBC, S3F = luminal B
vs TNBC, S3G = ER+ vs ER-.
Additional file 6: Table S3. Set-wise Results of Differentially Abun-
dance/Expression Analysis. List of differentially expressed intracellular
mRNAs and interstitial fluid miRNAs from pairs which were either com-
mon across sets (Table S3.1) or unique to sets (Table S3.2).
Additional file 7: Figure S4. Module Relationships. The hierarchical
clustering and heatmap show how similar the modules are (correlation
scale on the side). The color assignment is reported as well on the X and
Y axes.
Additional file 8: Table S4. Intramodular Connectivity. The table
contains results from the intramodular connectivity analysis, including
gene name, the module a gene belonged to, and interconnectivity
scores; kTotal (whole network), kWithin (within module), kOut = kTotal-
kWithin, and kDiff = kWithin-kOut. Additionally, the table includes
information about whether a gene was annotated as an oncogene |
tumor suppressor gene | dual role gene | driver gene | fusion gene in the
COSMIC census gene set, or in the filtered results of CancerMine text-
mining. The columns “DE Gene” and “Gene from Network” denote if a
gene was found to be differentially expressed in any comparison and
whether it was included in one of the miRNA-mRNA network, respect-
ively. The genes are ranked based on interconnectivity within modules.
Additional file 9: Figure S5. Intra-tumor mRNA Co-expression Modules.
Results of weighed Gene Co-expression Network Analysis. Upper part of
plot shows the clustering of the genes co-expressed in the 31 modules
from Weighed Gene Co-expression Network Analysis (WGCNA). Grey de-
notes that the gene was not assigned to any module. Modules are
named by their color. Lower part of plot shows the correlation between
patient clinical variables and modules.
Additional file 10: Figure S6. Overlap of Differentially Expressed
mRNAs with Co-expressed mRNAs. Venn diagrams, depicting the overlap
between differentially expressed mRNAs from contrasts, with modules,
which were correlated with the patient clinical feature of interest.
Additional file 11: Figure S7. Heatmaps of DE intra-tumor mRNAs
levels. Heatmaps showing the separation of tissue samples, based on the
best DE mRNA candidates from Weighed Gene Co-expression Network
Analysis (WGCNA). S7.A: luminal (A + B), Her2-enriched vs TNBC, S7.B: TIL
scores, S7.C: tumor grade (plus clusters minus genes from the TILs com-
parison) and S7.D: estrogen receptor status. Color scale denotes expres-
sion levels, purple = high expression, and yellow = low expression.
Additional file 12: Figure S8. Results of miRNA Co-abundance Network
Analysis. WGCNA resulted in three miRNAs co-abundance modules, de-
noted Module 1 (Blue, S7 A), Module 2 (Turquoise S7 B) and Module 3
(Red, S7 C). Shapes indicate which contrast a given miRNA was differen-
tially abundant within. X-axis = name of miRNA, y-axis = log fold change
for miRNA in contrast.
Additional file 13: Table S5. Interstitial Fluid miRNA and Intra-Tumor
mRNA Targets Supported by Databases. Differentially abundant miRNAs
with predicted mRNA target(s) from interaction networks and WCGNA,
supported by cancer miRNA databases. Databases were: (I) CMEP (Circulat-
ing MicroRNA Expression Profiling) http://syslab5.nchu.edu.tw/CMEP/ (II)
dbDEMC database of (Differentially Expressed MiRNAs in human Cancers)
http://www.picb.ac.cn/dbDEMC/ and (III) miRCancer (microRNA Cancer As-
sociation Database) http://mircancer.ecu.edu/download.jsp. Database in-
formation on miRNA expression is included, e.g. directionality in comparison,
experimental design.
Additional file 14: Table S6. Oncogenes and Tumor Suppressors in
Co-expression Modules. Co-expressed genes from modules that were an-
notated as oncogenes, tumor suppressors, dual role genes, driver genes
or fusion genes by COSMIC and/or CancerMine. As CancerMine is a pre-
diction tool, we imposed a cut-off of minimum of 10 annotations/cita-
tions for a gene (cancer other and pan-cancer) and a minimum of 5
annotations/citations for genes specifically associated with breast cancer
(See Materials and Methods).
Additional file 15: Table S7. Experimental Support for miRNA and
Gene Target Interaction. Prediction Differentially abundant tumor
interstitial fluid miRNAs and their experimentally validated intracellular
gene targets with support from MiRTarBase (Chou et al., 2017), release
7.0.
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